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Abbreviations 
AIH:  autoimmune hepatitis 
ALD:  alcoholic liver disease 
ALK:  activin-like kinase 
ALT:  alanine aminotransferase  
SMA: smooth muscle actin 
BDL:  bile duct ligation 
CCL4:  carbon tetrachloride  
CD1d:  CD1d deficient 
CLD:  chronic liver disease 
CM:  conditioned media 
DAMP: danger associated molecular pattern 
DMP1: dentin matrix protein 1 
DSPP: dentin sialophophoprotein 
EMT:  epithelial mesenchymal transition 
ERK:  extracellular signal regulated kinase 
FFPE:  formalin fixed, paraffin embedded 
Gli:  glioblastoma 
GSK3: glycogen synthase kinase-3
H&E:  hematoxylin and eosin 
Hh:  hedgehog 
HIF-1: hypoxia-induced factor 1
HSC:   hepatic stellate cell 
IBSP:  integrin binding sialoprotein or bone sialoprotein 
Inh:  indian hedgehog 
J18-/-: J18 chain deficient 
LMNC: liver mononuclear cell 
LPC:  liver progenitor cell 
LPS:  lipopolysaccharide 
MAPK: mitogen activated protein kinase 
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MCD:  methionine choline deficient 
MEPE: matrix extracellular phosphoglycoprotein 
MF:   myofibroblast 
MMP:  matrix metalloproteinase 
NAFLD:  nonalcoholic fatty liver disease 
NASH:  nonalcoholic steatohepatitis 
NKT:  natural killer T 
OPN:   osteopontin 
PBC:  primary biliary cholangitis 
PCLS:  precision cut liver slice 
PI3K:  Phosphoinositide-3 kinase 
PSC:  primary sclerosing cholangitis 
Ptc:  patched 
SIBLING: small integrin binding, N-linked glycoprotein 
Shh:  sonic hedgehog  
Smo:  smoothened 
SR:  Sirius red 
Src:  Src kinase  
TGF-: transforming growth factor  
TIMP:  tissue inhibitor of metalloproteinase 
TLR:  toll-like receptor 
TNF-: tumor necrosis factor 
WT:  wild type 
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Capítulo 1 
El desarrollo de fibrosis en enfermedades hepáticas crónicas (CLD) como las hepatitis víricas B o 
C, la enfermedad de hígado graso no alcohólica (NAFLD) y la alcohólica supone un reto sin 
resolver en clínica. Actualmente, no existe ningún tratamiento antifibrótico que reduzca o revierta 
la progresión de la fibrosis hepática en pacientes con CLD (1). Por tanto, los individuos con 
fibrosis hepática corren el riesgo de desarrollar cirrosis, y complicaciones como cáncer hepático y 
fallo hepático, en donde el único tratamiento es el transplante (2, 3). Además, se prevé que la 
prevalencia de CLD incremente en las próximas décadas, debido principalmente a la epidemia de 
los factores de riesgo para el desarrollo de NAFLD, que incluye la obesidad, el síndrome 
metabólico, y la diabetes mellitus tipo 2 (4, 5). 
 
La fibrosis hepática resulta de una reparación fallida después de un daño (6). La reparación 
involucra los esfuerzos de múltiples tipos celulares (células estelares (HSC) o pericitos hepáticos, 
células progenitoras (LPCs), células endoteliales, y células inmunes). Durante el daño hepático 
agudo (como el provocado por fármacos o la resección hepática), se produce la expansión de 
LPCs y pericitos para reemplazar las células epiteliales que mueren (hepatocitos y colangiocitos), 
mientras el endotelio sinusoidal regula el tráfico hepático de los distintos subgrupos de células 
inmunes para eliminar los restos celulares que estimulan la regeneración de nuevas células 
epiteliales (6, 7). La recuperación se produce cuando el insulto se elimina, y entonces las células 
muertas se reemplazan con nuevas y funcionales células epiteliales. Por el contrario, esta 
reparación “restauradora” no tiene lugar durante el daño hepático crónico; la activación sostenida 
de los pericitos hepáticos y la reprogramación aberrante de las LPCs lleva al depósito y acumulo 
del exceso de colágeno, induciendo fibrosis. La fibrogénesis es perpetuada, o incluso amplificada 
porque se produce el reclutamiento de células inmunes con efecto profibrogénico mas que el de 
subgrupos que resuelvan la fibrosis (8). Estudios recientes muestran que la reparación hepática 
está finamente regulada por múltiples moléculas de señalización, y que la dicotomía en la 
respuesta hepática, es decir reparación restaurativa versus reparación desregulada, puede ser 
explicada en parte por las alteraciones provocadas en estas vías de señalización. 
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Estas moléculas de señalización incluyen citoquinas, factores de crecimiento y morfogenos.  
Previamente, mi investigación se centró en el papel de la vía Hedgehog (Hh), que orquesta la 
construcción de tejido durante el desarrollo fetal (9, 10). Encontré que en NASH se produce la 
resurrección de la vía Hh, y que la muerte de hepatocitos provoca la liberación de ligandos Hh, 
que promueven la viabilidad y la proliferación de las LPC vecinas y la acumulación de 
miofibroblastos (MF, es decir HSC activadas) (11, 12). En concordancia con los hallazgos en 
cultivos celulares, animales salvajes que desarrollan fibrosis tras daño hepático también activan la 
vía Hh. Es de destacar, que animales con excesiva señalización Hh muestran mayor acumulación 
de MF y LPCs y desarrollan más fibrosis (13, 14). Encontré que la señalización Hh también 
provoca la reprogramación (transición mesenquimal-epitelial, EMT) de LPCs, que además induce 
la producción de matriz y fibrosis (15 – 17), y activa la respuesta inmune. Así, el “cross-talk” entre 
células estromales (HSC y LPCs) y células inmunes dirigido por la señalización Hh regula la 
respuesta inmune del daño hepático y provoca la activación de MF y LPCs, la desregulación de la 
reparación hepática y la fibrogénesis. Durante este tiempo, otro grupo de investigación demostró 
que en el promotor de osteopontina (OPN) hay sitios de unión con Glioblastoma (Gli, factores de 
transcripción aguas debajo de la vía Hh), y sugirió que la señalización Hh podría regular la 
transcripción de OPN (18). 
 
OPN es una citoquina pro-inflamatoria y una proteína de la matriz extracelular que se 
sobreexpresa en inflamación tisular, fibrosis y en malignidad (19). Es de destacar, que los 
animales deficientes en OPN muestran pobre cicatrización del tejido, es decir menos fibrosis, y 
están protegidos frente al desarrollo de cáncer, mientras que la sobreexpresión de OPN conduce 
al exceso de fibrosis y al desarrollo espontaneo de tumores (20, 21). Se han asociado altos 
niveles de OPN en suero e hígado con la acumulación de neutrofilos en un modelo de 
steatohepatitis alcohólica (22, 23) y se ha mostrado que la OPN secretada aumenta la activación 
de NKT y que promueve la acumulación de neutrofilos (24), mientras que los ratones OPN-/- 
están protegidos frente a la hepatitis inducida por Concavalina A. Todas estas observaciones  
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me llevaron a hipotetizar que la sobreexpresión de OPN in CLD promueve la fibrinogénesis 
activando células estromales e inmunes. 
 
En esta tesis primero introduciré el concepto de reparación hepática y presentaré los mecanismos 
implicados en la fibrosis hepática. A continuación describiré los cuatro estudios planteados para 
dar respuesta a esta hipótesis. 
 
Para dilucidar el papel de OPN en fibrosis hepática se ha utilizado una combinación de técnicas 
moleculares e inmunohistoquímicas, cultivos celulares y diferentes modelos animales de daño 
hepático. La relevancia de estos resultados en la enfermedad humana fue confirmada con 
estudios de expresión y función de OPN en tejido hepático y HSCs de pacientes que sufrieron 
transplante hepático por etapa final de enfermedad hepática.  
 
En resumen, el conjunto de estudios que se describen en esta tesis muestran: 
 
1. Durante el daño hepático crónico, la sobreexpresión de OPN, inducida por la 
activación de la vía Hh, promueve la fibrosis hepática 
 
La OPN se sobreexpresa de manera significativa en hígados de pacientes con NASH cirrótico, 
hígado graso alcohólico (ALD), hepatitis autoinmune (AIH), colangitis biliar primaria (PBC), y 
colangitis primaria esclerosante (PSC), y en varios modelos murinos de daño hepático incluido el 
de NASH fibrosis inducido por una dieta deficiente en metionine y colina (MCD). Nosotros 
mostramos que la OPN derivada de LPC puede actuar de forma paracrina para activar a HSC 
quiescentes en MF secretoras de colágeno. Las HSC también secretan OPN que auto-regula su 
fenotipo fibrogénico. Por otro lado, la neutralización de OPN reprime la fibrogenesis de HSC in 
vitro y reduce la fibrosis hepática in vivo. 
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A través de experimentos que demuestran que Gli y OPN co-localizan en células hepáticas, y que 
los niveles de mRNA de OPN incrementan con agonistas de Smoothen, y disminuyen con 
antagonistas de Smoothen confirmamos la hipótesis de que OPN está regulada por Hh. A través 
del uso de aptameros para OPN, que neutralizan la OPN circulante, verificamos que OPN es una 
diana clave aguas debajo de la señalización Hh y no viceversa ya que el neutralizar OPN no 
ejerce ningún efecto en la expresión celular de Gli2 (diana de Hh), pero reduce de manera 
significativa la expresión genética fibrogénica, incluso en células deficientes en Ptc con una 
actividad de la vía Hh incrementada. Los resultados explican porque a la par de evidenciar que 
los ratones OPN-/- están protegidos frente al desarrollo de NASH fibrosis, observamos que el 
contenido hepático en células Gli2 (+) y OPN (+) aumentan en paralelo según la fibrosis avanza 
en pacientes con NAFLD. 
 
2. La OPN interactúa con leptina en NASH. 
Al igual que la vía Hh, la OPN es importante como efectora, aguas abajo, de la fibrogenesis 
inducida por leptina. Es de destacar, que la neutralización de OPN anula la activación de HSC 
independientemente de la presencia de leptina exógena. Este hallazgo es importante ya que se 
ha evaluado en distintos estudios la posible utilidad de la administración de leptina a aquellos 
pacientes con hipoleptinemia y NASH. Sin embargo, si la leptina es directamente pro-fibrogénica, 
la administración de leptina exógena podría conllevar el empeoramiento de la fibrosis. Mientras 
que neutralizar la leptina en aquellos pacientes con exceso de leptina y avanzada fibrosis en 
NASH podría ser una estrategia útil anti-fibrótica, pero al mismo tiempo podría aumentar la 
ingesta y el peso corporal y con ello el riesgo metabólico, evitando así el efecto beneficioso. Por 
tanto, en estos casos neutralizar OPN podría ser una atractiva estrategia para afrontar la 
fibrogénesis inducida por los altos niveles de leptina. 
 
3. La OPN modula la respuesta de LPC  
La respuesta de LPC (o la reacción ductular en humanos) es predictiva de fibrosis. Por ello, la 
respuesta de reparación asociada a las LPC puede ser una diana de gran valor para inhibir la 
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fibrosis en CLD. Además de inhibir la activación de HSC, el tratamiento con aptameros o 
anticuerpos anti-OPN atenúa tanto in vivo como in vitro la respuesta de LPC. Nosotros mostramos 
el mecanismo por el que OPN regula la viabilidad de LPC, y regula directamente el fenotipo de las 
LPCs, sobreexpresando genes mesenquimales y reprimiendo los epiteliales. La neutralización de 
OPN inhibe la migración de LPC en el proceso de cicatrización y en ensayos de transmigración. 
Nosotros mostramos que estos efectores celulares actúan por modulación de la vía TGF-: La 
neutralización de OPN reprime los niveles de fosfo-Smad2/3 (indicativos de reducida activación 
de TGF-) y mantiene los niveles de los co-represores transcripcionales, ski y SnoN. 
 
4. La OPN derivada de células NKT hepáticas promueve fibrosis en NASH 
He reportado en trabajos anteriores que la activación de la vía de Hh en CLD aumenta la 
acumulación de las células NKT (16). En este trabajo, nosotros confirmamos y ampliamos esos 
hallazgos mostrando que la fibrogénesis en ratones que desarrollan NASH inducido por la dieta 
depende directamente de las células NKT y que las acciones fibrogénicas de las células NKT 
están directamente mediadas por OPN. En comparación con los animales WT, dos cepas de 
ratones deficientes en células NKT (J18-/- and CD1d-/-) mostraron una marcada atenuada 
fibrosis tras 8 semanas de dieta MCD. 
 
En resumen, estos hallazgos confirman que la OPN promueve la fibrogenesis hepática, y 
sugieren que la OPN puede ser una atractiva diana anti-fibrótica porque modula distintos 
mecanismos coordinados. 
 
Relevancia clínica 
Numerosas evidencias sugieren que la OPN es un efector clave en alteraciones metabólicas (25). 
La OPN esta incrementada en tejido adiposo inflamado, en endotelio vascular inflamado, y está 
sobreexpresada en la enfermedad isquémica de corazón y en diabetes tipo 2 (26 – 29). Los 
animales deficientes en OPN también muestran mejoría en la sensibilidad periférica a la insulina y 
en los perfiles metabólicos (mejora el manejo de lípidos y glucosa) (25). Los resultados aquí 
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mostrados apoyan la idea de que OPN puede ser una diana para beneficiar a pacientes con 
fibrosis en avanzado NASH. Estos resultados son de alta relevancia en clínica ya que se han 
desarrollado anticuerpos y aptameros de humano para inhibir las acciones de OPN que podrían 
ser usados para tratar a pacientes con NASH avanzado. 
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Chapter 1 
The development of fibrosis in chronic liver diseases (CLD) such as viral hepatitis B or C, alcoholic 
liver disease, autoimmune liver diseases, and nonalcoholic fatty liver disease (NAFLD) presents a 
vast unmet clinical challenge. At present, there is no effective anti-fibrotic treatment that halts or 
reverses the progression of liver fibrosis in patients with CLD (1). Individuals with liver fibrosis are 
therefore, at risk of developing cirrhosis, and complications such as liver cancer and liver failure, 
for which the only potential treatment is a liver transplant (2, 3). Furthermore, the prevalence of 
CLD is predicted to increase in coming decades due to the global epidemic of major risk factors for 
NAFLD including obesity, the metabolic syndrome, and type 2 diabetes mellitus (4, 5). 
 
Liver fibrosis is the result of ‘mis-repair’ following injury (6). Normal liver repair involves the 
concerted efforts of multiple cell types (hepatic stellate cells (HSC) or liver pericytes, liver 
progenitor cells (LPCs), endothelial cells, and immune cells). During acute liver injury (such as 
following acute drug injury or liver resection), expansion of LPCs and pericytes occur to replace 
dying epithelial cells (hepatocytes and cholangiocytes), while sinusoidal endothelium regulates the 
trafficking of immune cell subsets in the liver to remove cellular debris which further stimulates 
regeneration of new epithelial cells (6, 7). Recovery occurs when the insult is removed, and dying 
cells are replaced by functioning new epithelial cells. By contrast, such ‘restorative’ repair does not 
occur during chronic liver injury; sustained activation of liver pericytes and aberrant 
reprogramming of LPCs lead to excess collagen deposition and accumulation (i.e. fibrosis). 
Fibrogenic outcomes are perpetuated, or even amplified by the preferential recruitment of ‘effector 
– profibrogenic’ immune cells rather than ‘fibrosis-resolving’ subsets (8). Recent studies show that 
liver repair is normally tightly regulated by multiple molecular signals, and that the dichotomy in 
liver outcomes (i.e. restorative repair vs. deregulated repair) may be explained in part, by 
perturbations in these signaling pathways.  
 
Some of these cellular signals include cytokines, growth factors, and morphogens. Previously, my 
research had focus on the role of the Hedgehog (Hh) pathway, which normally orchestrates tissue 
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construction during foetal development (9, 10). I found that resurrection of the Hh pathway occurs 
in NASH, and that dying hepatocytes release Hh ligands which promote the viability and 
proliferation of neighboring LPCs and the accumulation of myofibroblasts (MF; i.e. activated HSC) 
(11, 12). Consistent with cell culture findings, wild-type (WT) mice which develop liver fibrosis after 
injury also activate the Hh pathway. Importantly, Patched-deficient (Pt+/-) mice with excessive Hh 
signaling exhibit even greater accumulation of MF and LPCs and develop more fibrosis (13, 14). I 
found that Hh signaling also induces the re-programming (epithelial-to-mesenchymal transition, 
EMT) of LPCs, which further increasing matrix-production and fibrosis (14), and also activates 
immune responses (15 – 17). Thus, stromal cell (HSC and LPCs) - immune cell cross-talk driven 
by Hh signaling regulates immune responses to liver injury and drives the activation of MF and 
LPCs, resulting in dysregulated repair and fibrogenesis. During this time, a group demonstrated 
Glioblastoma (Gli, downstream transcription factors of the Hh pathway) binding sites in the OPN 
promoter and suggested that Hh signaling might regulate also OPN transcription (18).  
 
OPN is a pro-inflammatory cytokine and matrix protein which is upregulated during tissue 
inflammation, fibrosis, and malignancy (19). Interestingly, mice deficient in OPN exhibit poor 
wound healing (i.e. less fibrosis), and are protected from cancers, while the overexpression of 
OPN leads to excess fibrosis and spontaneous tumour development (20, 21). Elevated serum and 
liver OPN are also associated with neutrophil accumulation in a model of alcoholic steatohepatitis 
(22, 23), and secreted OPN was shown to augment NKT activation and promote neutrophil 
accumulation (24), while OPN-/- mice are protected from Concavalin-A hepatitis. These 
observations led me to hypothesize that overexpression of OPN in CLD promotes fibrogenesis by 
activating stromal and immune cells.  
 
In this thesis, I will first introduce the concept of liver repair and summarize mechanisms of liver 
fibrosis. I will then describe the four studies which were aimed at addressing the hypotheses.  
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A combination of cell culture, immunohistochemistry, and molecular techniques in association with 
mouse models of liver injury were used to elucidate the mechanistic roles of OPN in liver fibrosis. 
Their relevance to human liver disease were confirmed by studies of OPN expression and function 
in human liver tissues and isolated HSCs from patients who had undergone liver transplant 
surgery for end-stage liver disease.  
 
In sum, the collective studies described in this thesis show that: 
 
1. OPN is upregulated by Hh pathway activation during chronic liver injury and 
promotes liver fibrosis   
OPN is significantly overexpressed in livers from cirrhotic human NASH, alcoholic liver disease 
(ALD), autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing 
cholangitis (PSC), and in several murine models of liver injury including the methionine choline 
deficient (MCD) diet model of NASH fibrosis. We show that LPC derived OPN can act in a 
paracrine fashion to activate quiescence HSC into collagen secreting MF. HSC themselves also 
secrete OPN which auto-regulate its fibrogenic phenotype. OPN neutralization on the other hand, 
represses HSC fibrogenesis in vitro and reduces liver fibrosis in vivo.  
 
By demonstrating co-localization of Gli and OPN in liver cells, and proving that expression of OPN 
mRNA is increased by a Smoothened agonist, and decreased by a Smoothened antagonist, we 
confirm the hypothesis that OPN is Hh regulated. Using OPN aptamers (which neutralizes 
circulating OPN), we verify that OPN is a key down-stream target of Hh signaling (rather than vice 
versa) because neutralizing OPN had no effect on cellular expression of Gli2 (a Hh target), but 
significantly reduced fibrogenic gene expression, even in Ptc+/- mouse derived cells with supra-
normal Hh pathway activity. Coupled with the evidence that OPN-/- mice are significantly protected 
from NASH fibrosis, the data explain why we observe that hepatic content of Gli2(+) cells and 
OPN (+) cells increased in parallel as liver fibrosis advanced in patients with NAFLD. 
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2. OPN interacts with leptin in NASH. 
Like Hh, OPN is an important downstream effector of leptin-induced fibrogenesis. Importantly, 
OPN neutralization abrogates HSC activation despite the presence of exogenous leptin. This 
finding is clinically informing because studies have evaluated the potential utility of leptin 
replacement in those with hypoleptinemia-NASH. However, if leptin is directly pro-fibrogenic, the 
supplementation of exogenous leptin may inadvertently lead to worsening fibrosis. While leptin 
neutralization in those with advanced NASH-fibrosis (and excess leptin) may be a useful anti-
fibrotic strategy, it is also likely to increase food intake and body weight (and metabolic risk), 
thereby negating any potential clinical benefit. Thus OPN neutralization could be an attractive 
strategy in the face of high leptin levels. 
 
3. OPN modulates the LPC response   
The LPC response (or the ductular reaction in humans) is predictive of subsequent fibrosis hence, 
targeting the LPC associated repair response may be of value in inhibiting fibrosis in CLD. In 
addition to inhibiting HSC activation, treatment with OPN aptamers or OPN neutralizing antibodies 
also attenuated the LPC response in vitro and in vivo. Mechanistically, we show that OPN is an 
important viability factor for LPCs, and directly regulates LPC phenotype by upregulating 
mesenchymal genes while repressing epithelial ones. OPN neutralization conversely inhibits LPC 
migration in both wound healing and transmigration assays. We find that these cellular effects 
occur via modulation of the TGF-pathway: OPN neutralization represses phospho-Smad2/3 
levels (indicative of reduced TGF-activation) and maintains levels of transcriptional co-
repressors, Ski and SnoN.  
 
4. Liver NKT cell derived OPN promotes NASH fibrosis 
I had previously reported that Hh pathway activation in CLD enhances hepatic accumulation of 
NKT cells (16).  Herein, we confirm and extend those findings by showing that fibrogenesis in mice 
with diet-induced NASH directly depends upon NKT cells and that the fibrogenic actions of NKT 
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cells are directly mediated by OPN. Compared with WT mice, two strains of NKT cell deficient 
mice (J18-/- and CD1d-/-) exhibited dramatically attenuated fibrosis after 8 weeks of MCD diet.  
 
In sum, these findings confirm that OPN promotes liver fibrogenesis, but also suggest that OPN 
could be an attractive anti-fibrotic target because it modulates multiple concerted mechanisms. 
  
Clinical Relevance 
 
Accumulating evidence suggest that OPN is a key effector of metabolic outcomes (2). OPN is 
significantly increased in inflamed adipose tissues, in inflamed vascular endothelium, and is 
upregulated in patients with ischemic heart disease and type 2 diabetes mellitus (26 – 29). Mice 
genetically deficient in OPN also exhibit improved peripheral insulin sensitivity and metabolic 
profiles (improved lipid and glucose handling) (25). The current data support the concept that 
targeting OPN may be beneficial in patients with advanced (NASH) fibrosis. These results are 
clinically important because humanized antibodies and aptamers which inhibit OPN actions have 
been developed, and may be used to treat patients with advanced NASH. 
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Chapter 2 
 
Fibrosis progression: Putative mechanisms and molecular pathways 
Syn WK and Diehl AM. In: Williams R and Taylor-Robinson SD, eds. Clinical Dilemmas in 
Non-Alcoholic Fatty Liver Disease, 1st edition.  John Wiley & Sons, Ltd. 2016; 61 – 71  
 
2.1. The Concept of Liver Repair 
Although a significant number of studies have been performed to help characterize NAFLD 
progression, the concept of repair is applicable across all CLD. 
 
The presence of dying and ballooned hepatocytes distinguishes NASH, a more advanced stage of 
NAFLD from simple steatosis (30, 31). Excessive free fatty acid influx, de novo lipogenesis, and 
impaired fatty acid oxidation lead to steatosis. Subsequent oxidative, cytotoxic and immune 
stresses then promote hepatocyte injury and death. Fat-laden hepatocytes which remain are 
unable to replicate and replace the lost hepatocytes, thereby triggering an expansion of LPCs (or 
stem cells) which attempt to restore architecture and function (32, 33). This LPC response is 
termed the ‘ductular reaction’ in humans, is a harbinger of fibrosis, and is characteristic of 
progressive liver disease (34). 
 
2.1.1. Hepatocyte Cell Death  
Gores and colleagues first reported an increased number of apoptotic hepatocytes in patients with 
NASH (30), and showed that the magnitude of apoptosis positively correlated with disease grade 
and stage (35). Mice deficient in caspase-2 (an initiator caspase responsible for long-chain fatty 
acid-induced cell death) exhibited reduced hepatocyte apoptosis and developed significantly less 
fibrosis when fed the high-fat (a model of steatosis and early NASH) or the MCD diet (a model of 
advanced NASH-fibrosis) (36). Pharmacologic approaches using a pan-caspase inhibitor similarly 
resulted in decreased active caspase-3, cell death, and fibrosis (37). These studies in animal 
models and in humans show that hepatocyte death is intricately linked to NASH progression.  
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2.1.2. Tissue Repair and Fibrogenesis 
The loss of functioning hepatocytes is accompanied by a compensatory proliferation of LPCs (i.e. 
liver stem cells) located in the Canal of Hering. These LPCs are surrounded by liver pericytes 
(referred to as HSC), portal fibroblasts, and an extracellular matrix enriched with endothelial cells 
forming neovasculature. LPCs, liver pericytes, stromal cells, and extracellular matrix collectively 
constitute the progenitor niche (38, 39). 
 
For many individuals with CLD, fibrosis (i.e. deregulated repair) is the general outcome. Although 
the reasons for this remain poorly understood, animal studies show that factors stimulating the 
progenitor response are pro-fibrogenic, and LPCs themselves are highly reactive and secrete high 
levels of pro-inflammatory and pro-fibrogenic cytokines. Fate-mapping and immunohistochemistry 
studies demonstrate that LPCs may be directly re-programmed, from an epithelial to a 
mesenchymal (EMT) (and possibly fibrogenic) phenotype (40, 41), and recently liver pericytes 
were identified as multi-potent progenitors capable of secreting collagen matrix as well as giving 
rise to new epithelial progenitors (i.e. mesenchymal to epithelial phenotype)  (42, 43). In addition, 
the progenitor-derived ‘secretome’ can act on neighbouring immune and endothelial cells to 
perpetuate and amplify fibrogenic outcomes (15, 44). Thus, the resultant ductular reaction 
observed during chronic injury should be considered a fibrogenic repair response (i.e. fibrosis 
promoting). ‘Restorative’ repair (where progenitors differentiate into new, functioning epithelial 
cells) occurs when the injury and pro-fibrogenic / pro-inflammatory stimuli are removed. 
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Figure 2.1.1: Link between Cell death and Fibrogenic Repair 
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Fig. 2.1.1: Link between cell death and liver fibrosis. 
Hepatocyte injury or death leads to the release of signalling factors (such as Hh) which promote the 
proliferation of ductular progenitors (or LPCs) and HSC as part of the repair response. Activated HSCs 
transform into collagen secreting myofibroblasts. LPCs secrete chemokines which recruit immune cells into 
the liver. In turn, recruited immune cells secrete even more cytokines and growth factors that perpetuate 
the fibrogenic response. LPCs may also undergo EMT into scar‐producing myofibroblasts.  
 
(From: Fibrosis progression: Putative mechanisms and molecular pathways by Syn WK and Diehl AM; in 
Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease, First Edition, 2016. John Wiley & Sons, Ltd.) 
 
 
 
2.2. Mechanisms of Liver Fibrosis 
 
Despite ample evidence showing that cell death triggers fibrogenesis, the mechanistic link remains 
poorly understood. Previously, it was proposed that phagocytosis of apoptotic hepatocytes by 
macrophages and HSC led to secretion of pro-fibrogenic mediators (45). In turn, these promoted 
HSC activation and fibrosis (an indirect mechanism). More recently, injury-associated 
inflammasome activation and release of damage-associated molecular patterns (DAMPs) were 
reported to promote disease progression (46). Inflammasome activation and DAMP release 
triggers immune cell recruitment, and RAGE, a receptor for high-mobility group box 1 (an example 
of DAMP), is required for LPC proliferation (47). Despite this, there is no convincing evidence for 
DAMPs directly activating HSC. 
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Recent studies suggest that soluble mediators released by injured and dying hepatocytes are 
major regulators of repair. Using cell culture and in vivo models, we showed that stressed or dying 
hepatocytes release Hedgehog (Hh) ligands, a morphogen normally responsible for orchestrating 
tissue development and cell fate (11). Hh ligands directly stimulate LPC and HSC (i.e. fibrogenic 
repair) (14, 48), provoke secretion of chemokines which lead to the recruitment of inflammatory 
cells (i.e. repair-associated inflammation) (15), and promote capillarisation of liver sinusoidal 
endothelium (44); features characteristic of progressive liver disease. Importantly, the level of Hh 
pathway activation correlated with the amount of injury and fibrosis (14, 49), suggesting that 
targeting the Hh pathway could be beneficial in the treatment of fibrosis. 
 
2.2.1. Local Regulation of Fibrogenesis  
Liver disease outcomes are dictated by the prevailing microenvironment. For example, an 
upregulation of pro-fibrogenic molecules would promote scar deposition and accumulation, while 
an excess of matrix degrading enzymes could facilitate resolution of fibrosis.  
 
Cytokines and growth factors are small soluble proteins secreted by immune cells, progenitor and 
ductular cells (cholangiocytes), liver pericytes, and endothelial cells, and are responsible for 
mediating cellular crosstalk (cell to cell communication) and regulating tissue metabolic responses. 
TGF- for example, is the prototypical pro-fibrogenic cytokine that is upregulated during CLD, and 
promotes LPC and pericyte proliferation and activation (50). Other novel mediators include Hh and 
OPN. 
 
The extracellular matrix is dynamically regulated, even during progressive fibrogenesis. The 
deposition of fibrillar collagens (especially collagen type 1), elastin, and matrix proteins by liver 
pericytes is matched by activities of matrix metalloproteinases (MMPs) (endopeptidases 
responsible for matrix degradation) produced by inflammatory cells and pericytes. MMPs in turn, 
are inhibited by extracellular inhibitors of metalloproteinases (TIMPs), which bind to active MMPs 
to inhibit their enzymatic activities (51, 52). The balance between MMPs and TIMPs alters the rate 
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Figure 2.2.1: Local Factors Regulating Liver Fibrogenesis 
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and pattern of matrix degradation, allowing for the fine regulation of matrix turnover. As an 
example, mice overexpressing TIMP1 developed more fibrosis, and failed to remodel the matrix 
during the fibrosis-resolution phase, while rats overexpressing MMP8 developed less fibrosis (53).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2.1: Local Factors Regulating Liver Fibrogenesis 
HSC activation occurs in the presence of pro-fibrogenic factors. Cytokines (e.g. IFN-g,TNF-,TGF-, IL4, 
IL13), growth factors (PDGF, CTGF), and morphogens (Hh, Wnt, Notch) are secreted by resident liver cells, 
as well as recruited immune cells (T cells, NK cells, NKT cells, T regulatory cells, gT cells, monocytes and 
macrophages). Matrix composition is dynamically regulated by MMPs responsible for matrix degradation. In 
turn, MMPs are inhibited by TIMPs.  
 
(From: Fibrosis progression: Putative mechanisms and molecular pathways by Syn WK and Diehl AM; in 
Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease, First Edition, 2016. John Wiley & Sons, Ltd.) 
 
Chronic liver injury is often associated with the recruitment of immune subsets (chronic 
inflammation) into the liver (54). Activated T and B cells, T-regulatory cells, natural killer and NKT 
cells, monocyte-macrophage subsets, dendritic and innate lymphoid cells, together constitute the 
innate and adaptive arms of the immune response. Collectively, these cells are responsible for 
maintaining liver tolerance on one hand, and for defence on the other (patrolling and clearance of 
cellular debris). Trafficking of immune cells into the liver is tightly regulated by chemokines 
(chemotactic cytokines), and expression of specific adhesion molecules on the liver sinusoidal 
endothelial surface (55). Mice genetically deficient in NKT cells are protected from NASH fibrosis, 
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while the accumulation of inflammatory macrophages promotes fibrogenesis. The role of 
macrophages is complex and recent studies suggest that a Ly6C intermediate – low subset is a 
key source of MMPs during fibrosis resolution (56). Thus, inhibiting recruitment of the ‘pro-
fibrogenic’ subset could prevent fibrosis development, while increasing recruitment of the ‘pro-
resolution’ subset could enhance fibrosis resolution through secretion of MMP12 and MMP13.  
 
 
2.2.2. Other Factors Regulating Liver Fibrosis 
Gut-Liver 
The human intestine normally harbours a diverse community of microbes that promotes 
metabolism and digestion in a symbiotic relationship with the host. Cumulative evidence show that 
changes to the intestinal microbiota (dysbiosis) lead to adverse liver outcomes. For example, 
compositional changes may increase energy extraction from food and result in the development of 
NAFLD (57). Feeding mice with a high-fat diet and inducing dysbiosis (by reducing the ratio 
between Bacteriodetes and Firmicutes, while increasing gram negative proteobacteria) accelerate 
fibrogenesis (58). Mechanistically, dysbiosis causes intestinal inflammation, a loss of intestinal 
barrier, and the translocation of microbial products (such as lipopolysaccharides, LPS). These lead 
to activation of pattern recognition receptors such as Toll-like receptors (TLR) 4, and perturbations 
in choline and bile acid metabolism. Interestingly, altered interactions between microbiota and 
inflammasome sensing may also govern the rate of NAFLD progression. To date, most of these 
data arise from animal experiments; better designed, longitudinal studies in humans are needed.  
 
Adipose-Liver 
The adipose tissue is a metabolically active, ‘cytokine factory’. The vast majority of individuals with 
NAFLD are overweight or obese, and in these individuals, the adipose tissue is enriched with 
immune infiltrates and secretes high levels of pro-inflammatory, pro-fibrogenic cytokines including 
leptin and tumour-necrosis factor alpha (TNF-(59)Serum leptin levels are significantly 
upregulated in patients with NASH, and have been shown to directly activate HSC and potentiate 
TGF- mediated effects (2, 60). By contrast, adiponectin levels are inversely correlated with fat 
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mass, and are suppressed in patients with NASH. Adiponectin exerts hepato-protective and anti-
fibrogenic effects, and mice with adiponectin deficiency developed more severe liver fibrosis after 
the high-fat diet (61).  
  
2.2.3. Putative Molecular Pathways 
Distinct mechanisms and multiple signals from liver cells, immune cells, and extra-hepatic tissues 
are integrated to generate a coherent repair response. We will highlight three molecular pathways 
currently being evaluated as targets for anti-fibrotic treatments.  
 
TGF- 
TGF-is the most potent pro-fibrogenic cytokine which induces fibrosis by direct activation of HSC 
and LPC, stimulating the synthesis of extracellular matrix, and inhibiting matrix degradation 
through the production of TIMPs (50). TGF-is secreted as an inactivated protein bound to a 
latency-associated peptide; when activated, TGF-then signals through its cognate receptors (i.e. 
activin-like kinase, ALK5), leading to the phosphorylation and nuclear translocation of its 
transcription factors, Smad2/3.  
 
The overexpression of TGF- promotes fibrosis while deletion of TGF-and Smad3 protects 
against fibrosis. Therefore, targeting this pathway appears to be attractive, and multiple 
approaches include anti-sense oligonucleotides (which inhibit TGF- mRNA), specific neutralizing 
antibodies (that interfere with ligand binding), natural TGF- antagonists (such as Smad7), and 
TGF- receptor - kinase blockers. However, as TGF- signaling is also important for tumour 
suppression, immune regulation, and cell differentiation, strategies that selectively target excess 
matrix deposition and accumulation will need to be developed. In a recent study, investigators 
described the selective delivery of an ALK5-inhibitor by coupling the compound to mannose-6-
phosphate human serum albumin (M6PHSA) which allows selective uptake by HSC (the main liver 
cell type responsible for matrix deposition) (62). In another, specific blockade or loss of HSC-
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expressing v integrins (by pharmacologic and genetic approaches, respectively) inhibited TGF-
activation and fibrogenesis (63).  
 
Hh signaling 
The Hh pathway is critical for tissue development and cellular responses including proliferation, 
apoptosis, and differentiation (9, 10). Excessive activation of the Hh pathway during development 
leads to childhood cancers such as medulloblastoma, while inactivity impairs wound healing.  
 
Components of the Hh pathway: 
The binding of Hh ligands (Sonic Hh or Indian Hh) to cognate receptor Ptc, on cell surface 
membranes leads to the depression of a co-receptor Smoothened (Smo). Depressed Smo is 
responsible for the transduction of signals downstream, and leads to the nuclear translocation of 
Gli1, 2, 3 transcription factors and expression of Hh-target genes (i.e. canonical Hh signaling). Ptc 
/ Smo-independent activation of the Hh pathway has also been described (i.e. non-canonical Hh 
signaling). 
 
Relationship between Hh and other pro-fibrogenic factors: 
The regulation of the Hh signaling pathway is complex, and future studies will be needed to fully 
understand the effects of canonical versus non-canonical pathways on liver outcomes. 
Interestingly, leptin and PDGF effects are mediated by increased secretion of Hh ligands 
(canonical signaling) (64), while TGF-and insulin-like growth factor enhances non-canonical Hh 
signaling (65). TGF-induces Gli transcription and Gli protein stabilization, while insulin-like 
growth factor inhibits Gli phosphorylation by glycogen synthase kinase-3(GSK-3), preventing its 
proteosomal degradation (i.e. more pathway activation). More recently, Hh signaling has also been 
shown to be a regulator of the LPS response, and links hypoxia with fibrosis via hypoxia-induced 
factor (HIF)-1 

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Summary of Hh actions: 
Injured (endoplasmic reticulum stress) or dying hepatocytes (pro-apoptotic stimuli) produce high 
levels of Hh ligands which act on surrounding liver progenitors, liver pericytes, sinusoidal 
endothelium, and immune cells (i.e. Hh-responsive cells) (11, 12).  
1. Hh ligands stimulate HSC proliferation and promote their transition into collagen-producing MF. 
In turn, HSC and MF secrete additional Hh ligands that amplify fibrogenesis (48, 64).  
2. Hh ligands induce proliferation of LPCs and promote reprograming of epithelial LPCs into 
mesenchymal (fibrogenic) phenotype (14). They also stimulate the secretion of chemokines such 
as CXCL16, which recruit inflammatory T and NKT cell subsets into the liver (15)  
3. Infiltrating immune cells are Hh-responsive, and activated T cells, NKT cells, and macrophages 
secrete Hh ligands which perpetuate liver injury (16, 17, 66)  
4. Activation of the Hh pathway activates sinusoidal endothelial cells, upregulates expression of 
key adhesion molecules and induces capillarisation of sinusoidal endothelium (44). 
 
Evidence of the Hh pathway in Human Liver Disease 
There is minimal Hh pathway activity in a healthy adult liver. By contrast, Hh pathway activation 
occurs in CLD (ALD, NAFLD, PBC, and chronic viral hepatitis), and activity of the Hh pathway 
parallels liver fibrosis stage (13, 14, 49, 67, 68).  
 
Modulating the Hh pathway in vivo:  
Activation of the Hh pathway also occurs in models of liver fibrosis (chronic carbon tetrachloride 
(CCL4), bile duct ligation (BDL), MCD diet (NASH), alcohol-induced injury, and genetic models of 
biliary fibrosis or NAFLD), and mice genetically engineered to exhibit greater Hh pathway 
activation developed more liver fibrosis than wild type mice (11, 13, 14, 69). Inhibiting the Hh 
pathway by pharmacological (i.e. cyclopamine or GDC-0449; both Smo antagonists) or genetic 
approaches (i.e. conditional deletion of the Smo gene) prevents fibrosis progression (14, 40, 41). 
The aggregate data in humans and mice suggest that the Hh pathway is a key regulator and 
integrator of fibrogenic signals (such as LPS-TLR4, leptin, TGF-, HIF-1). Hh pathway inhibitors 
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such as Vismodgib (GDC-0449) are already licensed for use in patients with advanced skin and 
haematological cancers, and should be evaluated as anti-fibrotic agents. 
 
2.3. Osteopontin (gene: Spp1) 
OPN is both a pro-inflammatory cytokine and a matrix protein. It is also known as secreted 
phosphoprotein 1 or early T cell activation factor, and is an acidic member of the small integrin-
binding ligand N-linked glycoprotein (SIBLING) family of proteins. OPN is highly upregulated in 
inflamed and fibrotic tissues of the skin, lungs, kidneys, and joints, and also in malignancy (19). 
OPN expression is regulated by cytokines (TNF-, IL-6, IL-1), growth factors, adipokines, and 
morphogens (Wnt and Notch). Interestingly, Glioblastoma (Gli, downstream transcription factors of 
the Hh pathway) binding sites have also been demonstrated in the OPN promoter, suggesting that 
Hh signaling might regulate OPN transcription (18).  
 
The OPN molecule contains an arginine-glycine-aspartic acid (RGD) sequence which can bind 
several integrins including v,v,v,,(70, 71). Enzymatic (e.g. by thrombin; tOPN) 
cleavage reveals a SVVYGLR amino-acid sequence in humans (or SLAYGLR in mice) which 
bindsand  (72 – 75). OPN also binds to CD44 via non-RGD domains to regulate 
migration, adhesion and proliferation, and engagement of OPN with integrins and CD44 leads to 
the activation of diverse signaling pathways (PI3K, MAPK, ERK, Src) (21, 76).  
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Figure 2.3.1: Osteopontin and SIBLINGs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3.1: Osteopontin and SIBLING family of proteins. OPN (SPP1) is located on chromosome 4, 
specifically in the region 4q22.1. It is part of a cluster of 5 genes that together form the SIBLING family, 
which contain the following genes: the dentin sialophosphoprotein (DSPP), the dentin matrix protein 1 
(DMP1), the bone sialoprotein (IBSP), the matrix extracellular phosphoglycoprotein (MEPE), and 
osteopontin (SPP1).  
 
(From: Briones-Orta MA ….Syn WK. Osteopontin splice variants and polymorphisms in cancer progression 
and prognosis. Biochim Biophys Acta. 2017 Feb 28; 1868(1):93-108) 
 
 
2.3.1. OPN in the Liver 
Elevated serum and liver OPN are associated with neutrophil accumulation in a model of alcoholic 
steatohepatitis (22, 23), and secreted OPN has been shown to augment NKT activation and 
promote neutrophil accumulation (24). By contrast, OPN-/- mice are protected from Concavalin-A 
hepatitis. In the beta-glucan hepatic granuloma model, OPN-/- mice also accumulated fewer liver 
macrophages, T cells, DC, expressed lower TNF-, and developed less severe injury (78). 
Importantly, mice deficient in OPN also exhibit poor wound healing (i.e. less fibrosis), and are 
protected from cancers, while the overexpression of OPN leads to excess fibrosis and 
spontaneous tumour development (20, 21). 
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Chapter 3 
 
Rationale:  
 
Previously, I had reported that activation of the Hh pathway occurs in CLD and that the degree of 
Hh pathway activity positively correlated with liver fibrosis stage (13, 14, 49). During CLD, 
secreted Hh ligands directly activate HSC into collagen-producing MF and stimulate LPC to 
undergo EMT which enhances fibrogenesis (14). Hh stimulated LPCs also secrete chemokines 
which recruit immune cells such as NKT cells into the liver (15, 16). NKT cells themselves secrete 
Hh and other factors which perpetuate the inflammatory response and amplify fibrogenesis.  
 
OPN is a pro-inflammatory cytokine and matrix protein which is highly upregulated in areas of 
inflammation and fibrosis, and promotes the recruitment of neutrophils in the Concavalin-A model 
of hepatitis (19, 24). OPN deficiency on the other hand, leads to impaired wound healing (i.e. less 
fibrosis) (20). These findings suggest that OPN and Hh exhibit similar functions. More recently, a 
group further described Gli binding sites in the OPN promoter and postulated that Hh signaling 
might regulate also OPN transcription (18).  
 
These findings therefore, led to me to hypothesize that OPN upregulation promotes 
fibrogenesis in CLD.  
 
Objectives: 
 
1. Evaluate the role of OPN in NAFLD / NASH fibrosis 
2. Study the interaction between OPN and Leptin in NASH 
3. Evaluate the role of OPN in the LPC response   
4. Evaluate the role of OPN in chronic liver inflammation  (NASH)
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Chapter 4 
 
4.1. Animal Studies 
All animal care and procedures were as per the NIH "Guide for the Care and Use of Laboratory 
Animals", and approved by relevant institutions: Duke University Institutional Animal Care and Use 
Committees, and the United Kingdom Home Office approval in accordance with the Animals 
(Scientific Procedures) Act of 1986 (University of Birmingham, PPL 40/3201). 
 
For study 5.1: 
C57BL/6 Patched-deficient (Ptc+/-) and WT (of the same background) mice were obtained from 
Jackson Laboratories (Bar Harbor, ME). Ptc+/- mice have only 1 copy of patched, a Hh-pathway 
repressor. Therefore, these mice are unable to silence Hh signaling and exhibit excessive Hh-
pathway activity. WT and Ptc+/- mice were fed the MCD diet (MP Biomedicals, Solon, OH) to 
induce NASH and liver fibrosis or control chow (MP Biomedicals, Solon, OH) (n= 8/group) for 8 
weeks. 129 Sv/J Black-Swiss OPN-deficient (OPN-/-) mice or littermate controls were also fed the 
MCD or control chow (n= 6/group). Because the 129 Sv/J strain was reported to be more sensitive 
to MCD treatment than the C57BL/6 strain (79), OPN-/- mice and littermate controls were fed the 
diets for 4, rather than 8, weeks.  
 
For study 5.2: 
To induce NASH and fibrosis, lean (WT) and obese (ob/ob) mice (males, C57BL/6; n= 5/group) 
were fed the MCD diets for 8 weeks. In the control arm, ob/ob and WT mice (n=5/group) were 
permitted ad libitum consumption of water and control chow.  
 
For study 5.3: 
Carbon Tetrachloride (CCL4): WT mice (n= 5/group) received twice-weekly intra-peritoneal 
injections of CCL4 (0.5 mg/kg, Sigma-Aldrich) for 6 weeks to induce liver fibrosis (80), or vehicle 
(mineral oil) 
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MCD diet:  WT mice (n= 5/group) were fed the MCD diet for 5 weeks to induce nonalcoholic 
steatohepatitis (NASH)-fibrosis, or control chow (14). 
 
3, 5,-Diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet:  WT mice (n= 5/group) were fed the DDC-
diet for 3 weeks to induce biliary-type fibrosis (81).  
 
Osteopontin neutralization in vivo:   
OPN-specific aptamers: Three additional studies were performed (4th study: CCL4; 5
th study: MCD; 
6th study: DDC) (n= 10/study; 5/group). OPN aptamers (OPN-R3) (which specifically neutralize 
circulating or extracellular OPN) or sham aptamers (OPN-R3-2) (its biologically-inactive mutant) 
(both synthesized by Dharmacon, Lafayette, CO) (82) were administered to mice by tail-vein 
injections (total of 4 injections per mouse), during the final week of dietary or chemical challenge. 
A 200ug dose of sham or OPN aptamers (in 100ul of PBS) was used as this was the dose 
previously shown to exhibit efficacy in vivo (83). All mice were sacrificed 24 hours after the final 
dose of aptamers.  
 
OPN neutralizing antibodies: MCD-fed mice (n= 5/group) were injected either control (IgG) or anti-
OPN (R&D) in the final week, as described above (4 injections; 50ug/injection), using an amount 
of anti OPN previously shown to be effective in reducing insulin-resistance in obese mice (25), and 
sacrificed 24 h after the final injection. 
 
For study 5.4: 
WT, CD1d-deficient (CD1d-/-), and J18-deficient (J18-/-) mice (RIKKEN, Japan) of B6 
backgrounds were fed MCD diet or control chow for 8 weeks.  
 
For all studies, mice were housed in 12 h-light/dark cycle with food and water ad libitum. Liver 
samples were obtained for RNA analyses and immunohistochemistry (IHC).  
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4.1.1. Mouse Liver IHC 
Liver tissue was fixed in formalin and embedded in paraffin (FFPE) and serial sections stained 
with hematoxylin and eosin (H&E). To quantify liver fibrosis, five micron sections were stained with 
picrosirus red (SR) (Sigma, St. Louis, MO) and counterstained with fast green (Sigma, St. Louis, 
MO). Immunohistochemical staining to detect OPN and Smooth muscle actin (SMA) was 
performed using the DAKO Envision System (DAKO Corporation) according to the manufacturer’s 
protocol. Antigen retrieval was performed by heating in 10 mM sodium citrate buffer (pH 6.0) or 
incubating with pepsin (00-3009; Invitrogen). Primary antibodies used are listed below in Table 1. 
Polymer-HRP anti-rabbit (Dako; K4003) and anti-goat (Santa Cruz; sc-2768; 1:250) were used as 
secondary antibodies. Antigens were demonstrated by diaminobenzidine (DAB) (DAKO). Double 
IHC was performed using Ferangi Blue or Vina Green, according to the manufacturer’s 
recommendation (Bio-Care Medical). Negative controls included liver specimens exposed to 1% 
bovine serum albumin and isotype matched antibodies. The proportion of tissue stained with SR, 
αSMA, and OPN were assessed by morphometric analysis with MetaView software (Universal 
Imaging Corp, Downtownington, PA).  For morphometric quantification, 40 to 50 randomly chosen, 
20x fields per section (excluding the major bile duct in each portal tract from consideration) were 
evaluated for each mouse liver section.  
 
Table 1: antibodies for mouse IHC 
 
 
 
 
 
 
 
 
 
Specificity Antibody Supplier 
OPN (mouse) AF808 R&D 
Sox9 5535 Millipore 
SMA  Ab5694 Abcam 
E-Cadherin 31955 Cell Signal 
K19  TROMA-3 Iowa Hybridoma Bank 
Gli2 18-732-292462 Genway 
- 48 - 
4.1.2. ALT determination 
Serum alanine aminotransferase (ALT) was measured using kits commercially available from 
Biotron Diagnostics (66-D; Hemet, CA) according to the manufacturers’ instructions.  
 
4.1.3. Hydroxyproline Assay 
Hydroxyproline content in whole liver specimens was quantified colorimetrically as previously 
described (80). 30 mg of freeze-dried liver samples were used. Hydroxyproline concentration was 
calculated from a standard curve prepared with high purity hydroxyproline (Sigma, St. Louis, MO) 
and expressed as mg hydroxyproline/g liver. 
 
4.1.4. ELISA assays for plasma OPN 
Peripheral blood was collected at the time of sacrifice, and plasma obtained and stored at -800C till 
analysis. Plasma OPN was measured using the commercially available OPN ELISA kit (R&D; 
DY441) and in accordance with the manufacturer’s instructions. All samples were run in duplicate, 
and expressed as pg/ml.  
 
4.2. Human studies 
Human studies were conducted in accordance with the Declaration of Helsinki (2008), and in 
accordance with NIH and respective Institutional guidelines for human subject research. Informed 
consent was obtained from participating subjects. Studies of samples acquired from the 
Hepatobiliary Unit in Birmingham were done in accordance with local ethical approval 
04/Q2708/41 and REC 2003/242 from the South-Birmingham Research Ethics Committee, UK  
 
4.2.1. Liver tissues 
De-identified FFPE liver sections of explanted liver tissues from individuals undergoing liver 
transplantation for NASH, ALD, PBC, or AIH-cirrhosis (n= 6/group) from the Liver and 
Hepatobiliary Unit, Birmingham, UK and Department of Pathology at Duke University were used. 
Liver sections from biopsy-proven NASH-related early and advanced fibrosis (n= 10/group) were 
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also used. Normal tissues were obtained from non-diseased livers removed during resection for 
colorectal hepatic metastases or from split-liver grafts. Freshly explanted AIH, NASH, ALD, PSC, 
and PBC-cirrhotic liver tissues (n= 5/group) were also snap-frozen and used for total liver RNA 
analyses.  
 
4.2.2. Human Liver IHC 
This was performed as described for mouse IHC. Primary antibodies used are listed in Table 2. 
Polymer-HRP anti-rabbit (Dako; K4003) and anti-goat (Santa Cruz; sc-2768; 1:250) were used as 
secondary antibodies.  Antigens were demonstrated by diaminobenzidine (DAB) (DAKO). The use 
of isotype matched control antibodies eliminated staining, demonstrating specificity.  
 
SR staining with quantification by morphometric analysis was performed as described in mouse 
IHC. For OPN quantification, 15 to 20 randomly selected x20 fields (excluding the major bile duct 
in each portal tract from consideration) were analyzed with the MetaView software.   
 
Table 2: antibodies for human IHC 
 
 
 
 
 
 
4.2.3. Serum or Plasma samples 
Plasma was taken from patients with early (n=25) or advanced NASH (n=25) at the time of liver 
biopsies, and stored at -800C till analysis.  
 
 
 
Specificity Antibody Supplier 
OPN (human) AF1433 R&D 
Gli2 18-732-292462 Genway 
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4.2.4. OPN ELISA  
Serum were taken from patients and stored at -800C till analysis. Serum OPN was measured 
using the commercially available OPN ELISA kit (R&D; DY1433) and in accordance with the 
manufacturer’s instructions. All samples were run in duplicate, and expressed as pg/ml.  
 
 4.3. Cell Cultures – HSC  
4.3.1 Human HSCs 
The human HSC line, LX-2, was cultured in serum-supplemented DMEM.  Primary human HSC 
were isolated as previously described (80). 
 
4.3.2. Rat or Mouse HSCs 
Primary HSCs were isolated from Sprague-Dawley rats, assessed for purity and viability, and 
seeded at a density of 3 x 102 cells/mm2 in DMEM supplemented with 10% fetal bovine serum 
(FBS) and penicillin (50 U/ml) /streptomycin (50 ug/ml) (80). A similar isolation/culture protocol 
was used for studies involving mouse primary HSC (16). Day 4 HSCs were used in all 
experiments. The mouse HSC line (GRX) was maintained in DMEM, 5% FBS, and 1% 
penicillin/streptomycin (84). 
 
4.3.3. Experiments using HSC: 
Studies of Hh and OPN in cultured HSC 
To evaluate the effects of Hh signaling on HSC, day 4 HSC cultures were grown for an additional 
24 h in medium containing either exogenous Hh agonist (SAG) at a concentration of 0.3uM, 5uM 
cyclopamine (Toronto Research Chemicals Inc., Toronto, Canada), an inhibitor of Hh-signaling, or 
5uM tomatidine (Calbiochem, San Diego, CA), a catalytically inactive analog of Cyclopamine (48, 
80) (tomatidine serves as a control for cyclopamine).  
 
In separate experiments, recombinant OPN (rOPN) or vehicle was added to cultures to assess 
their effects on HSC activation. 100ng/ml dose was used in this study because it stimulated 
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greatest effects in vitro (85). The effects of neutralizing circulating or extracellular OPN were 
assessed by treating HSC with OPN RNA aptamer or sham aptamer (82). Aptamers (6.66 ug/ml or 
100 nmol/l) were added to medium for 48 h prior to harvest. This concentration of OPN aptamer 
was shown to inhibit adhesion, migration and invasion in the MDA-MB-231 breast cancer cell line 
(which highly expresses OPN and is a standard tool for evaluating OPN actions). 
 
4.3.4 OPN knockdown 
HSCs were seeded in 24-well plates, 5x104 per well, serum-starved (0.1% FBS/DMEM), and 
treated with 5 µg/ml polybrene (Santa Cruz, Dallas TX) in low-serum media (0.1% FBS/DMEM) 24 
h prior to infection. Cells were trypsinized and suspended in 250 µl media, and treated with 4 µl 
lentiviral particles (2x104 IFU) containing shRNA constructs specifically targeting OPN (Santa Cruz 
sc-36130-V)  or non-targeting scrambled control shRNA (Santa Cruz sc-108080). The plates 
containing cell and viral particle suspensions were immediately centrifuged at 750 x g for 30 min at 
25ºC, and placed in the incubator for 48 hr. After the infection period, cells were then split, allowed 
to recover for 24 hr, then subjected to 8 µg/ml puromycin selection for 72 hr. 
 
4.3.5. Leptin in HSC 
For studies that involved treatments with leptin (100ng/ml; R&D systems, Minneapolis, MN) and/or 
adenoviral vectors, day 7 HSC cultures were cultured overnight in serum-depleted medium (0.1% 
FBS) before treatments were initiated.  
 
Cells were treated with recombinant leptin (100ng/mL; R&D systems, Minneapolis, MN) for 48 h. 
For PI3K inhibition, LY294002 (25 uM; Cell Signalling Technology, Danvers, MA) was applied to 
cells 30 mins prior to treatment.  
 
4.3.6. Adenoviral Transduction of Primary Rat HSC 
Ad5GFP, which contains the GFP gene driven by the cytomegalovirus promoter, was used as a 
control virus. The Ad5dnAkt and Ad5myrAkt viruses express the dominant negative and activated 
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forms of Akt, respectively (60). Pilot studies demonstrated that maximally efficient transduction 
occurred at a multiplicity of infection of 100. Subsequent experiments were carried out with this 
multiplicity of infection for 24 h; virus-containing medium was then aspirated and replaced with 
fresh medium. 
 
All cell experiments were performed at least in duplicate. Total RNA and protein were harvested 
before and at the end of the treatments, and analyzed by QRTPCR and immunoblotting, 
respectively.  
 
4.3.7. Co-culture experiments:  
Cholangiocyte – HSC 
The immortalized, but non-transformed, murine immature cholangiocyte cell line, 603B was 
maintained in 6-well, cell-culture plates (Costar 3516, Corning Incorporated) in standard culture 
media as previously described (86, 87). At 90% confluence, cholangiocyte-conditioned media 
(CM) were harvested and added to primary HSC cultures together with OPN aptamers or sham 
aptamers; HSC were harvested 2 days later and mRNA expression was analyzed by QRTPCR. 
Experiments were performed in duplicate wells and repeated twice. 
 
NKT – HSC 
Primary liver mononuclear cells (LMNC) were isolated as previously described (17, 88), and 
cultured in complete NKT media, with or without the NKT cell ligand, Galactosylceramide (GC) 
(100 ng/ml; Axxora, Cat no 306027, CA), for 24 hours. GC specifically activates iNKT cells (16, 
89). GC-activated LMNC CM (LMNC-CM) were then added to primary murine HSC, in the 
presence or absence of the Hh neutralizing antibody, 5E1 (10ug/ml; Iowa Hybridoma Bank), the 
Smoothened antagonist GDC-0449 (Selleck, Houston), or vehicle for 48 h and RNA was 
harvested for QRTPCR. Experiments were performed in duplicate wells and repeated twice. In 
separate experiments, LMNC-CM was added to primary murine HSC with either sham aptamers 
(100nmol/l) or OPN aptamers (100nmol/l) for 48 h, and RNA harvested as above.  
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4.3.8. Transmigration and wound healing assays 
For transmigration assays, cells were cultured in the upper chamber of a 24-well transwell system 
(3 µm membrane, Nunc™ Polycarbonate Membrane Inserts, Thermo Fisher Scientific, 
Loughborough, UK). After 24 h, the upper side of the membrane was gently wiped with a cotton 
bud to remove non-migrated cells, and the membrane was stained with crystal violet solution (1% 
crystal violet, 25% methanol) for 10 minutes, washed in PBS and allowed to air dry. Cells migrated 
to the bottom side of the membrane were visualized on an inverted microscope, and quantified 
using the average number of migrated cells per 15 randomly-selected fields. 
 
Standard wound healing assays were performed by growing cells to a confluent monolayer, and 
making a manual scratch using a P200 pipette tip. A reference mark was made on the wound and 
photographed at time 0, and compared 12 h later. Wound diameters were quantified using NIH 
Image J version 1.48v (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, 
Maryland, USA, http://imagej.nih.gov/ij/, 1997-2012]). 
 
4.3.9. Precision Cut Liver Slice Organ Culture 
In order to study the impact of OPN neutralization in the intact liver we used a Krumdieck Tissue 
Slicer (TCS Biologicals) to cut aseptic, 250 m thick slices of live liver tissue, which could be 
studied for up to 48 h ex-vivo. Liver tissue was incubated in Williams E media (Sigma) 
supplemented with 2% FCS, 0.1μM dexamethasone (Sigma) and 0.5μM insulin (Novo-Nordisk). 
Tissues were stimulated with recombinant leptin, in the presence of sham aptamers or OPN 
aptamers. At the end of treatment, liver slices were collected for RNA analysis by QRTPCR. Cell 
viability was evaluated by measuring the content of ATP with the ATP Bioluminescence Assay Kit 
CLS II (Roche, Basel, Switzerland), normalized against the total amount of proteins quantified by 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA). The threshold of viability 
is 4 nmol/mg protein of ATP measured 2 h after recovery (i.e. time 0 h in Fig 5A). 
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4.3.10. Semi-quantitative real-time PCR (QRTPCR) 
Total RNA was extracted from cell cultures using TRIzol® (Life Technologies, Carlsbad, CA) 
according to manufacturer’s instructions. RNA (1 µg) was reverse transcribed to cDNA templates 
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). For semiquantitative RT-PCR, cDNA (25 
ng) was amplified using SYBR® Green PCR Master Mix (Life Technologies) and oligonucleotide 
primers for specific targets sequences on an Applied Biosystems 7500 Real-Time PCR system. 
RT-PCR parameters were as follows: denaturating at 95°C for 10 minutes, followed by 40 cycles 
of denaturing at 95°C for 15 seconds and annealing/extension at 60°C for 60 seconds. Threshold 
cycles (Ct) were automatically calculated by the system software. Target gene levels were 
determined relative to the S9 ribosomal protein house-keeping gene using the 2–ΔΔCt method. 
Primers used are listed in Table 3. 
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Table 3: primers for QRTPCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Forward 5’->3’ Reverse 5’->3’ 
Mouse   
S9 AGCCGGCCTAGCGAGGTCAA CGAAGGGTCTCCGTGGGGTCA 
OPN TGGCAGCTCAGAGGAGAAGAAGC GGGTCAGGCACCAGCCATGTG 
Col1a1 AATGGCACGGCTGTGTGCGA AGCACTCGCCCTCCCGTCTT 
E-
Cadherin 
CCGCGGCGCACTACTGAGTT CACTGAGCTCGGGTGCGGTC 
Id2 CCCGGTGGACGACCCGATGA TCTGGGGGATGCTGGGCACC 
Snail GGACCCCCAGTCGCGGAAGA GGCAGCGTGTGGCTTCGGAT 
K19  GTGAAGATCCGCGACTGGT AGGCGAGCATTGTCAATCTG 
SMA GATGAAGCCCAGAGCAAGAG CTTTTCCATGTCGTCCCAGT 
TGF GACAGCCCTGCTCACCGTCG CCCGAGGGCTGGTCCGGAAT 
Sox9 CGACTACGCTGACCATCAGA GACTGGTTGTTCCCAGTGCT 
Gli2 ACCATGCCTACCCAACTCAG CTGCTCCTGTGTCAGTCCAA 
InH ACAGATGGAATGCGTGTGAA CCGAACCTTCATCTTGGTG 
Rat   
S9 AGCCGGCCTAGCGAGGTCAA CGAAGGGTCTCCGTGGGGTCA 
SMA GTGGATCACCAAGCAGGAGGAGT CATAGCACGATGGTCGATTG 
Col1a1 CTGCATACACAATGGCCTAA GGGTCCCTCGACTCCTA 
OPN ATG GCT TTC ATT GGA GTT GC GAG GAG AAG GCG CAT TAC AG 
Human   
S9 GACTCCGGAACAAACGTGAGGT CTTCATCTTGCCCTCGTCCA 
Beta actin TGGCATCCACGAAACTACCT ACGGAGTACTTGCGCTCAG 
Col 1a1 CGTCGGAGCAGACGGGAGTT TCCGCTCATGCGTGGCCTCA 
SMA AGGAGAGCAGGCCAAGGGGCTA CTTGGCTGGGCTGCTCCACAC 
OPN AGGCATCACCTGTGCCATACCA TGGCCACAGCATCTGGGTATTTGT 
Sox9 TTCAGTGGCGCGGAGACTCG GCAAAAGTGGGGGCGCTTGC 
TGF GTGCTGCTCCACTTTTAACT AACCCACAACGAAATCTATG 
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4.3.11  Western blot 
Whole cell proteins were homogenized using standard RIPA buffer (Tris-buffered saline [TBS], 1% 
NP-40, 0.1% SDS) containing Protease Inhibitor Cocktail Tablets from Roche (Indianapolis, IN). 
Protein concentration was measured using BCA Protein Assay Kit from Pierce Biotechnology 
(Rockford, IL). 20 to 40 μg of protein were separated by polyacrylamide gel electrophoresis and 
transferred to nitrocellulose membranes (0.45 m; Invitrogen). After blocking with 5% non-fat milk 
(Carnation, Swampscott, MA) in TBS (20mmol/L Tris, pH 7.5, 150 mmol/L NaCl) containing 0.1% 
Tween-20 (TBS-T), nitrocellulose membranes were incubated with primary antibodies. 
SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) was used to detect 
specific antibody-HRP complexes. The band density was measured using the Alphalmager 3400 
Analysis System (Alpha Innotech, San Leandro, CA).  Primary antibodies used are listed in Table 
4. 
 
Table 4: antibodies for western blot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity Antibody Supplier 
OPN (mouse) AF808 R&D Systems 
OPN (human) AF1433 R&D Systems 
pSMAD2 138D4 Cell Signaling 
SnoN H-317 Santa Cruz 
Ski H-329 Santa Cruz 
SMAD7 B-8 Santa Cruz 
Keratin 19 ab15463 Abcam 
Sox9 AB5535 Millipore 
β-actin AC-74 Sigma 
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4.3.12  FACS analysis 
Primary LMNC 
Isolated LMNCs were stained with FITC-conjugated CD3 (BD; 561806), Pacific blue-conjugated 
CD56 (Biolegend), and PE-conjugated OPN (R&D, IC14331P), and analyzed using the BDTM LSR 
II (BD Biosciences) at the flow cytometry core facility at the Duke Human Vaccine Institute Flow 
Cytometry Core Facility, Duke University Medical Center.  
 
4.3.13     Statistical Analysis 
Results are expressed as means ± SEM. Significance was established using the Student’s t-test 
and analysis of variance. Differences were considered significant when p < 0.05. 
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Chapter 5 
 
5.1 Role of OPN in NASH and Liver Fibrosis 
 
Osteopontin is induced by Hedgehog Pathway Activation and Promotes Fibrosis 
Progression in Nonalcoholic Steatohepatitis  
(Syn WK et al. Hepatology. 2011 Jan; 53(1):106-15.) 
 
 
NASH is a potentially serious form of chronic liver injury because it increases the risk of 
developing cirrhosis and primary liver cancer. The mechanisms that lead to these outcomes have 
not been fully elucidated, but appear to involve responses that are triggered by hepatocyte 
apoptosis (30, 31) and MF accumulation (90).  Certain apoptotic stimuli were recently reported to 
induce hepatocyte production of Hh ligands (11).  Hh ligands, in turn, elicit a number of fibrogenic 
actions by engaging their receptors on Hh responsive liver cells, such as ductular type cells, HSC, 
and NKT cells.  In HSC, for example, Hh pathway activation functions in a cell-autonomous 
fashion to promote transition of quiescent (Q)-HSC to MF-HSC, enhance MF-HSC proliferation, 
and inhibit MF-HSC apoptosis (48).  Activating Hh signaling in other types of liver cells (e.g., 
ductular cells and NKT cells) also causes these cells to generate factors that promote MF-HSC 
accumulation by paracrine mechanisms (14, 16).   
 
OPN, a pro-inflammatory cytokine and integrin-binding ligand (21, 91, 92), is highly expressed in 
many inflamed tissues and plays a critical role in wound healing (93 – 95).  Recently, Gli binding 
sites were demonstrated in the OPN promoter, prompting speculation that Hh signaling might 
regulate OPN transcription (18). This concept is potentially relevant to NASH-related liver fibrosis 
because Hh pathway activity increases in parallel with fibrosis stage in NASH.  Moreover, in other 
tissues, OPN is secreted by the types of cells (e.g., NKT cells and fibroblasts) that mediate 
fibrogenic repair in NASH (24, 96).  Evidence that OPN mRNA increases during culture-related 
activation of Q-HSC to MF-HSC (96) and correlates with fibrosis severity in biliary atresia (97) 
further support a potential role for OPN in cirrhosis pathogenesis.   
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Figure 5.1.1
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We manipulated Hh pathway activity in mice and cultured cells to determine effects 
on OPN production, and examined whether or not reducing OPN impacted Hh signaling or 
fibrogenesis. The results support and advance the concept that OPN is a Hh-target gene and 
reveal a previously-unsuspected role for OPN as a proximal mediator of Hedgehog’s fibrogenic 
actions in NASH. 
 
5.1.1. Upregulation of OPN parallels Hh pathway activation during MCD diet-induced NASH.  
WT mice (n= 8/group) develop hepatic necro-inflammation, accumulate markers of MF-HSC, and 
exhibit liver fibrosis after 8 weeks of MCD diet. Ptc+/- mice (with haplo-insufficiency of Ptc, a factor 
that constrains Hh signaling) exhibit worse liver fibrosis than WT mice after MCD diet exposure 
(Fig 5.1.1). This suggests that Hh pathway activation promotes fibrosis progression in this model 
of NASH, but the exact mechanisms involved need to be determined.   
 
 
 
 
 
 
 
Fig. 5.1.1: Hh pathway activation worsens liver 
fibrosis during diet-induced NASH. 
WT and Ptc+/- mice were fed control chow or the MCD 
diet for 8 weeks, and then sacrificed to assess serum 
ALT and severity of liver fibrosis. (A) Serum ALT levels 
in WT mice fed control or the MCD diet (IU/L; mean ± 
SEM). (B) SR quantification by morphometric analysis 
and (C) representative SR staining after MCD diet. 
Sections from 4 animals were used per group and 10 
randomly selected, 200X fields chosen for analysis by 
the Metaview software. (D) Hepatic hydroxyproline 
content in both WT and Ptc+/- mice. *P<0.05 vs. 
control-chow fed mice 
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Hh pathway activation results in nuclear accumulation of Gli proteins (downstream targets of Hh 
signaling) (98), and Gli proteins may regulate transcription of OPN, a potential pro-fibrogenic factor 
(78, 99, 100).  Therefore, we compared OPN expression in WT mice that were fed either control or 
MCD diets for 8 weeks. In WT mice, MCD diets caused a significant induction of OPN mRNA 
(>10-fold) and protein (about 2-fold) expression (Fig 5.1.2A, B). Ptc+/- mice exhibited even 
greater up-regulation of OPN expression when fed MCD diets (Fig 5.1.2B, C).  The latter finding 
supports the concept that Hh signaling increases OPN expression. In both strains, the OPN-
immunoreactive cells were mostly ductular in appearance (Fig 5.1.2D). Double immunostaining for 
Gli2 and OPN in liver samples from NASH patients demonstrated that Gli2-(+) ductular cells that 
co-expressed OPN localized within fibrous septae (Fig 5.1.2E).  
 
 
 
Fig. 5.1.2: Osteopontin (OPN) expression parallels 
Hedgehog (Hh) pathway activation during diet-
induced NASH. 
WT and Ptc+/- mice were fed as described in Fig. 
5.1.1. (A) OPN mRNA in WT mice fed control or MCD 
diet. Results are expressed as fold change relative to 
control-chow fed mice; mean ± SEM. *P<0.05 vs. 
control-chow fed mice. (B) Total hepatic OPN 
expression by Western blot and densitometry. (C) 
Representative OPN immunostaining after MCD 
treatment in WT and Ptc+/- mice (final magnification 
400X), and quantification by morphometry. Sections 
from 4 animals were used per group and 8 randomly 
selected 200X fields. Results are expressed as fold 
change (% positive staining) relative to chow-fed 
control mice, and graphed as mean ± SEM. *P<0.05 
vs. control mice. (D) Representative OPN (+) biliary 
ductular cells in murine NASH-fibrosis (630X). (E) 
Representative OPN (blue) and Gli2 (brown) double-
positive ductular cells in human NASH-cirrhosis 
(400X).  
 
 
5.1.2. MCD diet-fed OPN-deficient mice developed less fibrosis 
To evaluate whether or not OPN directly contributed to the fibrogenic response evoked by MCD 
diets, and gain further insight into the relationship between OPN and the Hh pathway, OPN-/- mice 
(n=12) and littermates (n=12) were fed MCD or control diets for 4 weeks. OPN deficiency had no 
obvious effect on expression of the Hh-target gene, Gli2, because both OPN-/- and littermates 
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showed similar induction of Gli2 mRNA (data not shown) and protein (Fig 5.1.3A) after 4 weeks of 
MCD diet. Despite apparent similarities in Hh pathway activity, however, the fibrogenic responses 
of OPN-/- mice were markedly attenuated when compared to that of their littermate controls. After 
MCD diet feeding, for example, OPN-/- mice accumulated 50% fewer SMA+ cells (Fig 5.1.3B) 
and significantly fewer SR stained fibrils (Fig 5.1.3C) than comparably-treated littermates.  These 
results suggest that the Hh pathway mediates its fibrogenic effects, at least in part, by inducing 
expression of OPN.  
 
 
 
 
Fig. 5.1.3: OPN-/- mice develop less fibrosis after 
MCD diet treatment 
129Sv/J OPN-deficient and littermates were fed MCD 
diet or control chow (n=6 mice/group/dietary treatment) 
for 4 weeks. At the end of treatment, mice were 
sacrificed. (A) Accumulation of Gli2 (+) cells in OPN-/- 
and littermates. Sections from 6 animals were used, 
and 8 randomly selected, 200X field chosen for cell 
counting. (B) SMA morphometry. Sections from 3 
animals were used at each time point and 10 randomly 
selected, 200X fields chosen for analysis. (C) SR 
quantification by morphometric analysis. Sections from 
6 animals were used and 10 randomly selected 200X 
field chosen for analysis. Results are expressed as fold 
change relative to chow-fed littermates and graphed as 
mean ± SEM. *P<0.05 vs. littermate control.  
 
 
 
 
5.1.3. Paracrine/Autocrine OPN stimulates HSC expression of fibrogenic genes   
Hh responsive bile ductular cells are major sources of OPN (Fig 5.1.2D).  Therefore, we treated 
primary cultures of rodent HSC with CM from monocultures of a cholangiocyte cell line, and 
assessed effects on HSC gene expression.  To determine if HSC responses were mediated by 
OPN, studies were repeated using cholangiocyte-CM plus OPN aptamers. Cholangiocyte-CM 
augmented HSC expression of -sma (Fig 5.1.4A) and collagen  (Fig 5.1.4B); OPN aptamer 
treatment repressed -sma induction by 50% and returned collagen expression to basal values, 
proving that paracrine signaling involving OPN promoted fibrogenic gene expression in HSC.  In 
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separate studies, other primary HSC cultures were treated with recombinant OPN (rOPN, 
100ng/ml) or vehicle for 24 h, and RNA was analyzed by QRTPCR (Fig 5.1.4C-D). rOPN also 
augmented expression of sma and collagen Ia1 expression. These findings support the concept 
that exogenous OPN can function as a paracrine factor to promote fibrogenic gene expression in 
HSC. 
 
 
Fig 5.1.4: Paracrine OPN stimulates HSC 
activation and collagen expression 
(A-B) Isolated mouse primary HSC were 
cultured for 4 days, and then treated with 
conditioned media (CM) from 
cholangiocytes, with or without OPN RNA 
aptamers for 48 h. (C-D) In separate 
experiments, primary HSC were directly 
treated with recombinant OPN (rOPN: 0 or 
100ng/ml) for 24 hrs, and then harvested for 
QRTPCR analysis. (A, C,) sma, (B, D) 
collagen mRNA. Mean ± SEM of duplicate 
experiments are graphed. *P<0.05 vs. 
vehicle treated stellate cells. 
 
 
 
 
Because another group has reported that MF-HSC themselves also express OPN (96), we next 
investigated changes in endogenous OPN gene expression during “spontaneous” culture-related 
activation of Q-HSC to MF-HSC.  We confirmed that HSC expression of OPN mRNA and protein 
increased significantly as Q-HSC transitioned to become MF-HSC (Fig 5.1.5A, B). Addition of 
OPN aptamers to day 4 cultures significantly repressed -sma and collagen gene expression, 
providing novel evidence that HSC-derived OPN may help to maintain the myofibroblastic 
phenotype of cultured HSC (Fig 5.1.5C, D).   As HSC become MF-HSCs, they repress expression 
of the Hh inhibitor, Hhip, induce expression of Hh ligands, and up-regulate various MF genes, 
while down-regulating markers of quiescence (48).  To clarify the relationship between Hh 
pathway activation and OPN expression, day 4 culture-activated MF-HSC were treated with 
cyclopamine to selectively inhibit Hh signaling. Cultures were harvested 24 h later, RNA was 
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isolated, gene expression was assessed by QRTPCR, and results were compared to parallel 
cultures that had been treated with tomatidine, an inactive cyclopamine analog. Inhibiting Hh 
signaling with cyclopamine attenuated induction of OPN gene expression (Fig 5.1.5E). 
Conversely, addition of the Hh agonist, SAG, augmented OPN gene expression significantly (Fig 
5.1.5F). Thus, endogenous OPN gene expression in MF-HSC is regulated, at least in part, by the 
Hh pathway.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1.5: Hh regulated OPN overexpression promotes HSC activation in an autocrine fashion 
Primary rat HSC were isolated and cultured for 0, 4 and 7 days. At the end of treatment, HSC were washed 
and cell lysates obtained for Western blot analysis. (A) OPN Western blot and densitometry. Primary 
human HSC (ph HSC) were also isolated and maintained till culture-activated to myofibroblasts (MF-HSC) 
and then harvested for RNA and analyzed by QRTPCR. The human HSC line LX2 was used as 
comparison. (B) OPN mRNA Q-HSC, MF-HSC, and LX2. In separate experiments, day 4 HSC cultures 
were treated with OPN aptamers or sham aptamers (control) for 48 h and RNA isolated for QRTPCR (C-D). 
(C) sma, (D) collagen mRNA. To assess if OPN expression is Hh-regulated, day 4 HSC were treated with 
Cyclopamine (Cyc), Tomatidine (Tom), or SAG for 24 h, and then harvested for RNA analysis (E-F). (E-F) 
OPN mRNA. Mean ± SEM of duplicate experiments are graphed. * p<0.05 vs. control (vehicle) treated or 
quiescent stellate cells. 
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Fig. 5.1.6: OPN is a downstream target of the Hh pathway 
WT and Ptc+/- primary HSC were placed in culture for 4 days and then harvested for RNA analysis by 
QRTPCR. (A) gli2, (B) opn mRNA; mean ± SEM of duplicate experiments are graphed. *p<0.05 vs. WT 
HSC. In separate experiments, Ptc+/- HSC were treated with OPN aptamers or sham aptamers (control) for 
48 h, and effects on fibrogenesis assessed by QRTPCR. (C) collagen, (D) sma, and (E) gli2 mRNA.  
Mean ± SEM of triplicate experiments are graphed. * p<0.05 vs. sham aptamer (control) treated HSC 
 
To determine the relative importance of OPN as a down-stream target of the Hh pathway in HSC, 
day 4 primary MF-HSC from Ptc+/- mice were incubated with OPN aptamers for 48 h. At baseline, 
HSC from Ptc+/- mice expressed 3-fold more gli2 mRNA than WT HSC, confirming that Ptc-
deficiency enhances Hh signaling (Fig 5.1.6A). Consistent with in vivo findings (Fig 5.1.1), Ptc+/- 
HSC also expressed more OPN mRNA than WT HSC (Fig 5.1.6B). Neutralizing OPN significantly 
reduced collagen and sma mRNA levels in the Ptc-deficient HSC (Fig 5.1.6C-D), but had little 
effect on gli2 mRNA expression (Fig 5.1.6E).  These findings suggest that the Hh pathway 
mediates induction of certain fibrogenic genes indirectly, via up-regulation of the Hh responsive 
gene OPN.   
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5.1.4. Evidence of OPN overexpression in humans with progressive NAFLD 
Because the mouse model of MCD diet-induced NASH differs in several regards from human 
NASH (101), it was important to determine if OPN overexpression occurred in patients with 
NAFLD. Coded liver sections from 11 patients with well-characterized NAFL (n = 3), NASH (n = 3), 
and NASH-related cirrhosis (n=5) were stained to demonstrate OPN, and then analyzed by 
computer-assisted morphometry. Expression of OPN was lowest in patients with NAFL and 
highest in patients with NASH-cirrhosis (Fig 5.1.7A-B). To further validate the association between 
NAFLD-fibrosis stage and OPN expression, total liver RNA was isolated from a separate cohort of 
36 individuals with early (Fibrosis stage F0-1) or advanced (F3-4) NASH-fibrosis (n=18/group) and 
analyzed by QRTPCR. In livers with advanced -fibrosis OPN gene expression was double that of 
livers with early fibrosis (Fig 5.1.7C).  Additional analysis was conducted using RNA and protein 
harvested from explanted livers with NASH-cirrhosis and residual tissue from non-diseased donor 
livers (n=6 per disease). Livers with NASH-cirrhosis contained over 10x more OPN protein (Fig 
5.1.7D) and 5x more OPN mRNA compared with non-diseased controls (Fig 5.1.8A).  
Interestingly, OPN was also significantly increased in livers from individuals with ALD (Fig 5.1.8A, 
B), PBC (Fig 5.1.8A, C), AIH, and PSC (Fig 5.1.8A), suggesting that OPN induction is a 
conserved response to chronic liver injury.  
 
 
 
 
 
Fig. 5.1.7: OPN overexpression in NAFLD patients 
Coded liver sections from patients with NAFL, NASH, and 
NASH-cirrhosis were stained for OPN and analyzed by 
computer-assisted morphometry. (A) Representative 
photomicrographs of liver sections from patients with 
NAFLD and normal liver from excess donor tissues (200X). 
(B) Quantitative analysis of OPN in all patients. Amount of 
OPN is expressed as percentage of stained cells per high-
powered field. *P <0 .05 vs. normal. Total liver RNA was 
isolated from individuals (n=18/group) with early or late 
NASH-fibrosis and analyzed by QRTPCR. (C) OPN mRNA. 
Mean ± SEM are graphed * p<0.05 vs early fibrosis. (D) 
Hepatic OPN protein from normal, ALD-cirrhosis and 
NASH-cirrhosis individuals     
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Fig. 5.1.8: Enrichment of hepatic OPN in patients with CLD 
RNA were harvested from explanted ALD-, NASH-, PBC-, PSC- and AIH-cirrhotic livers and analyzed by 
QRTPCR. Liver sections from ALD and PBC-cirrhosis were immunostained for OPN. (A) OPN mRNA (n= 
6/group); results expressed as fold change relative to normal donor livers, mean ± SEM. *p<0.05 vs. 
normal. (B) Representative OPN immunostaining in ALD-cirrhosis (100X), and (C) PBC-cirrhosis (100X). 
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5.2. Interaction between OPN and Leptin in NASH Fibrosis 
 
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) 
fibrosis  
(Coombes JD ….Syn WK. Biochim Biophys Acta. 2016 Jan; 1862(1):135-44) 
 
 
The HSC is the major source of extracellular matrix, and thus, the key effector of the repair 
response (3). When activated by cytokines (e.g. TGF-), growth factors (connective tissue growth 
factor), or morphogens (Hh, Wnt), quiescent HSC transition into motile, collagen-secreting MF 
(102). HSCs are also capable of responding to circulating neurotransmitters and hormones (103, 
104). Leptin is an adipocyte-derived hormone which, not only controls energy balance and food in-
take, but also modulates the liver repair response (105 – 107). Binding of leptin to HSC surface 
receptors for instance, upregulates key fibrogenic genes SMA and collagen 11, while mice 
deficient in leptin (i.e. ob/ob mice) are protected against liver fibrosis (105, 108, 109). In humans, 
serum and tissue leptin levels are highly elevated in the obese (110, 111), helping to explain at 
least in part, why obese, NAFLD individuals are more at risk of developing liver fibrosis. 
 
Recently, we reported that leptin-induced liver fibrosis occurs via activation of the Hh pathway (60) 
and that upregulation of the Hh ligand and downstream target genes requires induction of the 
PI3K/Akt signaling. Hh pathway activation promotes transition of quiescent HSC into activated 
myofibroblasts (25), while inhibition of Hh reverses this phenotype.  Similarly, the addition of 
LY294002 (a PI3K inhibitor) or cyclopamine (a specific Hh pathway inhibitor) to leptin-treated HSC 
blocked all actions of leptin, thus revealing that the PI3K – Hh axis is necessary for leptin to exert 
its fibrogenic effects.  
 
OPN is highly expressed in a variety of inflamed tissues, and plays a critical role in tissue repair 
(19, 112), thus functionally resembling Hh. Interestingly, mice with excessive Hh pathway activity 
express more liver OPN and develop worse liver fibrosis, while inhibition of Hh signaling (with 
cyclopamine) in HSC represses OPN levels (Results: 5.1). These results demonstrate that OPN 
is a downstream effector of Hh, and led us to hypothesize that OPN and leptin may interact in 
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HSC to promote NASH progression. Using a combination of HSC cultures and diet-induced model 
of NASH, we confirm that OPN is a downstream effector of leptin, and is required for fibrotic 
outcomes in NASH.  
 
5.2.1. Leptin-deficient (ob/ob) livers contain less OPN and are less fibrotic than control (WT) 
livers after MCD treatment 
Chronic exposure to the MCD diet induced comparable epithelial cell injury in WT (leptin-intact) 
and ob/ob (leptin-deficient) mice (113, 114). WT mice developed significant liver fibrosis in 
response to the MCD diet, as evidenced by ~6-fold accumulation of SR stained collagen fibrils 
(Fig. 5.2.1A - C), ~2.5-fold increase in hepatic hydroxyproline content (Fig. 5.2.1D), and a 4-fold 
upregulation in collagen 11 mRNA (Fig. 5.2.1E). Collagen deposition was accompanied by the 
accumulation of SMA+ cells (Fig. 5.2.2A, B), and induction of key fibrogenic genes, SMA (~4-
fold) (Fig. 5.2.2C), TGF-1 (~3-fold)(Fig. 5.2.2D). OPN+ cells and OPN mRNA (Fig 5.2.3A - C) 
were significantly increased (greater than 10-fold). 
 
 
 
 
 
 
Fig. 5.2.1: Leptin-deficient (ob/ob) mice develop 
less NASH-fibrosis than leptin-intact (WT) mice 
WT and ob/ob mice were fed control chow or the 
MCD diet for 8 weeks. Livers were harvested for 
IHC, QRTPCR, and biochemical analysis. 
Representative staining are shown. (A) H&E. (B) SR 
staining. (C) SR morphometry. (D) Liver 
hydroxyproline measurements. (E) Collagen 11 
mRNA. Results are expressed as fold changes 
relative to WT control, and graphed as mean ± 
SEM. *p<0.05 vs. WT control 
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By contrast, fibrosis was significantly less in ob/ob mouse livers after the MCD diet (Fig. 5.2.1): 
ob/ob livers contained nearly 50% fewer SR stained collagen fibrils (Fig. 5.2.1B, C), ~2.5-fold less 
liver hydroxyproline (Fig. 5.2.1D), ~50% less TGF-1 mRNA, and exhibited minimal induction of 
collagen 11, SMA and OPN mRNA (Fig. 5.2.1E, 5.2.2C, D, and 5.2.3C). The degree of weight 
loss however, was similar between (WT and ob/ob) MCD-fed groups. These findings confirm that 
leptin directly promotes fibrogenesis in MCD-induced NASH (60,105, 113). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2.2: ob/ob mice exhibit repressed fibrogenesis in response to the MCD diet 
(A) SMA staining. (B) SMA morphometry. (C) SMA mRNA. (D) TGFmRNA. Results are expressed as 
fold changes relative to WT control, and graphed as mean ± SEM. *p<0.05 vs. WT control 
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Fig. 5.2.3: OPN expressing HSC accumulate in NASH fibrosis 
WT and ob/ob mice were fed control chow or the MCD diet for 8 weeks. Livers were harvested for IHC and 
QRTPCR. Representative staining are shown. (A) OPN staining. (B) OPN morphometry. (C) OPN mRNA; 
results are expressed as fold change relative to WT control mice. (D) OPN (brown) and Desmin (marker of 
HSC) (green) – double immunostaining (magnification x400); graph shows number of OPN / Desmin 
double-positive cells per HPF (quantified by cell counting); black arrows indicate cells which co-express 
OPN and Desmin. All results are graphed as mean ± SEM; *p<0.05 vs. WT control mice or otherwise 
indicated. 
 
 
 
5.2.2. OPN is a downstream effector of Leptin in HSC 
Leptin is a pro-fibrogenic adipokine which directly activates HSC (105, 106). Recently, we reported 
that OPN also promotes HSC activation (Results: 5.1). In this study, the loss of circulating leptin 
was directly associated with repressed liver OPN (Fig 5.2.3A - C), and attenuated liver 
fibrogenesis (Fig. 5.2.1, 5.2.2). These observations led us to hypothesize that leptin could regulate 
OPN expression in HSC. Herein, we confirm by double immunohistochemistry that desmin (+) 
HSC co-expressed OPN (Fig 5.2.3D). Importantly, the number of desmin / OPN double (+) HSC 
accumulated by more than 5-fold in MCD-fed mice, but this increase was almost abolished in 
ob/ob-MCD mice.  
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To determine if leptin was directly influencing OPN expression in HSC, we treated the mouse HSC 
line, GRX, with recombinant leptin (rleptin) for 48 h; cells were then harvested for RNA analysis by 
QRTPCR. rLeptin activated HSC, upregulated OPN, and key fibrogenic markers, SMA, collagen 
11, TGF (~2-fold) (Fig 5.2.4A – D). We next investigated if loss of OPN would inhibit leptin 
fibrogenic effects. To this end, GRX were treated with lentiviral particles which containin shRNA 
constructs specifically targeting OPN (GRX-shOPN). Compared with control (GRX-shScr) (GRX 
infected with lentiviral particles containing non-targeting scrambled shRNA), OPN knockdown 
(~80%) (Fig 5.2.5) significantly abrogated leptin fibrogenic effects by >90% (Fig 5.2.4). As 
increased cell migration is an important feature of activated HSC, we further examined if OPN 
knockdown (under leptin-stimulated conditions) would impair HSC migratory properties. Migration 
was assessed by semi-quantitating the dimensions of a wound dividing the confluent monolayer 
12 h after the scratch. OPN knockdown led to ~15% less wound healing compared with controls 
(p<0.05) (Fig 5.2.4E). Comparable results observed in the modified cell-invasion assay (Fig 
5.2.4F). OPN knockdown led to 50% fewer GRX cells invading across the insert membrane.  
 
 
Figure 5.2.4: OPN loss abrogates leptin fibrogenic 
effects in HSC  
HSC (mouse GRX line) with OPN knockdown (shOPN) 
and control HSC (shScr) were treated with recombinant 
leptin (or vehicle) for 48 h. Cells were then harvested and 
RNA analyzed by QRTPCR. (A) OPN mRNA. (B) SMA 
mRNA. (C) Collagen 11 mRNA. (D) TGFmRNA. 
Results are expressed as fold changes relative to shScr, 
and graphed as mean ± SEM. Wound-healing and 
transmigration studies in shOPN or shScr HSC were 
performed under leptin-treated conditions (E-F). (E) 
Wound healing; migration was quantified by measuring 
the distance dividing the two sides of the monolayer. 
Mean (% wound closure) ± SEM were graphed. (F) 
Transmigration was evaluated 24 h after seeding of cells, 
by counting crystal violet-stained cells on the underside 
membrane in 15 random HPF. Mean cell numbers ± SEM 
were graphed. *p<0.05 vs shScr or otherwise indicated. 
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Fig. 5.2.5: OPN knockdown in GRX HSC 
Mouse HSC line (GRX) was infected with lentiviral 
particles containing non-targeting scrambled shRNA 
(shScr) or OPN-targeting shOPN (shOPN). (A) 
Western blot and (B) densitometry showing OPN 
knockdown using lenti-shOPN compared with control 
lenti-shScr. (C) OPN mRNA. Results were expressed 
as fold change relative to shScr. *p<0.05 vs. shScr 
 
 
 
We verified these results using OPN-specific aptamers which neutralize circulating OPN (82, 83), 
in the presence of rleptin. OPN neutralization blunted SMA expression (Fig. 5.2.6A), and 
significantly repressed collagen 11 and TGFmRNA (~50%) (Fig. 5.2.6B, C). Similar to 
knockdown experiments, OPN neutralization also inhibited migratory properties of HSC, leading to 
impaired wound healing (~30%) and transmigration (~50%) across membranes (Fig. 5.2.6D, E).  
In aggregate, these results demonstrate that OPN is a downstream effector of leptin induced 
fibrogenesis, and that OPN is a potential anti-fibrotic target. 
 
 
 
 
 
Fig. 5.2.6: OPN neutralization inhibits fibrogenic 
effects of leptin in GRX HSC 
HSC were treated with sham aptamers (100nM) or OPN 
aptamers (100nM) under leptin-stimulated (100ng/ml) 
conditions, for 48 h. Cells were then harvested and RNA 
analyzed by QRTPCR. (A) SMA mRNA. (B) Collagen 
11 mRNA. (C) TGFmRNA. Results are expressed as 
fold changes relative to sham-aptamer and graphed as 
mean ± SEM. Wound-healing and transmigration studies 
in sham or OPN aptamer-treated HSC were performed 
under leptin-treated conditions (D-E). (D) Wound healing; 
migration was quantified by measuring the distance 
dividing the two sides of the monolayer. Mean (% wound 
closure) ± SEM were graphed. (E) Transmigration was 
evaluated 24 h after seeding of cells, by counting crystal 
violet-stained cells on the underside membrane in 15 
random HPF. Mean cell numbers ± SEM were graphed. 
*p<0.05 vs sham-aptamer 
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5.2.3. OPN expression is regulated by Leptin-PI3K/Akt signaling in HSC 
Leptin receptors couple with PI3K and activate Akt, which is required for leptin-associated 
fibrogenic effects (115, 116). Leptin activates the Hh pathway in HSC, but this is blocked by 
LY294002, a PI3K inhibitor (60). Because OPN is a downstream target of the Hh pathway 
(Results: 5.1), we investigated if OPN could similarly be regulated by the PI3K/Akt pathway. GRX 
HSCs were treated with leptin in the presence or absence of LY294002. LY294002 significantly 
repressed OPN mRNA by >50% (Fig 5.2.7A), and downregulated fibrogenic genes SMA, 
collagen 11, and TGFby up to 60%(Fig 5.2.7B – D). OPN knockdown in combination with 
LY294002 further enhanced repression of fibrogenic genes by an additional ~20% (Fig 5.2.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2.7: OPN is PI3K regulated and enhances fibrogenesis in GRX HSCs 
HSC with OPN knockdown (shOPN) and control HSC (shScr) were treated with recombinant leptin, with or 
without LY294002 (a PI3K inhibitor). Cells were then harvested and RNA analyzed by QRTPCR. (A) OPN 
mRNA. (B) SMA mRNA. (C) Collagen 11 mRNA. (D) TGFmRNA. Results are expressed as fold 
changes relative to shScr-Leptin, and graphed as mean ± SEM. *p<0.05 vs. shScr-Leptin 
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To exclude the possibility that observed responses were GRX specific, we repeated experiments 
using freshly isolated rat HSC. Comparable with GRX HSCs, leptin treated, primary rat HSC 
upregulated OPN, SMA, and collagen 11 mRNA by ~2-fold (Fig 5.2.8A – C), but this effect was 
completely blocked in the presence of LY294002. OPN mRNA in particular, was repressed below 
basal expression. Adenoviral-mediated transfer of dominant negative Akt (dnAkt) similarly inhibited 
leptin mediated changes in OPN, SMA, and collagen 11 mRNA (Fig 5.2.8A – C), but infection 
with mock adenoviral vectors (AdGFP; control) did not. By contrast, infection with the constitutively 
active Akt vector (Ad5myrAkt) induced OPN, SMA, and collagen 11 mRNA to levels 
comparable with leptin-treated cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2.8: OPN is a downstream target of leptin and is PI3K/Akt regulated in primary HSC 
Freshly isolated HSC were treated with leptin (or vehicle), with or without LY294002.  Additional HSC were 
also pre-treated with Ad5dnAkt (or Ad5GFP) prior to treatment with leptin (100 ng/mL) or Ad5mryAkt alone. 
RNA was isolated and changes in gene expression evaluated by QRT-PCR. (A) OPN mRNA. (B) SMA 
mRNA. (C) Collagen 11 mRNA. Results are expressed as fold changes relative to vehicle-treated HSC, 
and graphed as mean ± SEM. *p<0.05 vs. vehicle. 
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5.2.4. OPN neutralization inhibits leptin-associated fibrogenesis in precision-cut liver slices  
To validate in vitro findings, we used an established liver organ culture system in which precision-
cut, viable mouse liver slices (PCLS) were stimulated with leptin, in the presence of sham or OPN 
aptamers. PCLS are useful because they can be cultured for several days and better reflect the 
multicellular in vivo conditions (3, 117). Liver slice viability was maintained as evidenced by the 
ATP assay (Fig 5.2.9A). Treatment with exogenous leptin upregulated liver slices OPN mRNA by 
~2-folds (Fig 5.2.9B), and induced SMA and collagen 11mRNA by ~20% (Fig 5.2.9C, D). 
Conversely, neutralizing OPN significantly repressed OPN and collagen 11mRNA, even beyond 
basal levels. No change in total slice SMA mRNA was detected.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.9: OPN neutralization abrogates fibrogenesis in PCLS 
Precision-cut, viable mouse liver slices (PCLS) (a liver organ culture system) were stimulated with leptin (or 
vehicle), in the presence of sham or OPN specific aptamers for 48 h. At the end of treatment, liver slices 
were harvested, viability assessed by ATP content, and RNA analyzed by QRTPCR. (A) ATP content 
(viability) in nmol/mg protein; hashed line denotes the accepted viability threshold. (B) OPN mRNA. (C) 
SMA mRNA. (D) Collagen 11 mRNA. Results are expressed as fold changes relative to vehicle-treated 
PCLS, and graphed as mean ± SEM. *p<0.05 vs. vehicle. 
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5.3. Role of OPN in the Liver Progenitor Cell Response and Fibrosis 
 
Osteopontin Neutralization Abrogates the Liver Progenitor Cell Response and Fibrogenesis 
in Mice  
(Coombes JD ….Syn WK. Gut. 2015 Jul; 64(7):1120-31) 
 
During CLD, restoration of liver mass and function in response to hepatocyte loss involves 
activation of liver progenitors within the liver (i.e. progenitor-associated repair response or ductular 
reaction) (32, 33, 34), which proliferate and differentiate into new hepatocytes and cholangiocytes 
(118,119). This pool of progenitors is heterogeneous, compromising the resident LPC or oval cell 
residing in the Canals of Hering (38), bone marrow-derived progenitors (120, 121), as well as HSC 
(41). HSC are liver fibroblasts which normally transition into collagen-producing MFs when 
activated (51, 52), but have recently been recognized as a multi-potent progenitor that interacts 
with the liver progenitor pool (41); thus, providing an explanation for the fibrogenic outcomes which 
accompany progenitor-cell expansion during persistent liver injury (i.e. fibrogenic-repair). These 
cell culture and mouse observations are supported by longitudinal human studies, which show that 
the ductular reaction is predictive of subsequent fibrosis (34,122). Hence, targeting the progenitor-
associated repair response may be of value in inhibiting fibrosis in CLD. 
 
Progenitor-cell activation is driven by a milieu of growth factors, and cytokines which accompany 
CLD (8, 123). Recently, we reported that injury-related re-activation of the Hh induces liver 
progenitors to proliferate, undergo EMT (i.e. upregulating mesenchymal, while repressing 
epithelial genes), and secrete factors that activate neighboring progenitors and matrix-producing 
cells (13 – 15, 48). OPN is a Hh-target, and a matricellular protein that is highly upregulated in 
fibrotic skin, lungs, kidneys, and joints (20, 124 – 126). Mice genetically deficient in OPN develop 
less fibrosis after certain injuries, suggesting that OPN may be a direct effector of the fibrotic 
process. Not surprisingly, HSC express high levels of OPN to auto-regulate their fibrogenic 
phenotype (Results: 5.1). However, the highest expression of OPN is seen in cells located in the 
liver periportal regions, and recent studies show that OPN is a key regulator of bone-marrow 
progenitor/stem-cell fate (127). These led us to hypothesize that OPN modulates the progenitor-
associated fibrogenic repair response during liver injury.   
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Despite prevailing data giving credence to OPN being an attractive anti-fibrotic target, and 
humanized antibodies to OPN being developed for inflammatory-joint diseases (126), no study has 
yet evaluated the impact of OPN neutralization in the treatment of fibrosis complicating CLD. 
Therefore, to evaluate these hypotheses, we studied the direct effects of OPN in cultures of LPCs, 
examined the effects of OPN neutralization (by OPN aptamers or OPN neutralizing antibodies) in 
three murine models of liver fibrosis, and corroborated findings with analysis of liver tissues from 
patients with CLD.  
 
5.3.1. OPN is upregulated in human CLD and is expressed by Sox9+ liver progenitors 
Coded liver sections from patients with NASH-cirrhosis (n= 5), ALD-cirrhosis (n= 5), and PBC (n= 
5) were stained to demonstrate OPN, Sox9, and K19. Compared with healthy livers, cirrhotic livers 
exhibit up to 15-fold more OPN protein (Fig 5.3.1A, Fig 5.3.2A) and 10-fold more OPN mRNA 
(Fig 5.3.2F). The highest level of OPN is expressed by cells located in the peri-portal regions. As 
expected, cirrhotic livers express more TGF-mRNA than healthy livers (Fig 5.3.2F) 
 
Because Sox9+ cells are bi-potent liver progenitors that arise from peri-portal Canals of Hering 
(128), we examined this LPC (oval cell) marker. As expected, cirrhotic livers contain up to 10-
times more Sox9+ cells (Fig 5.3.1B, Fig 5.3.2B) and upregulate Sox9 mRNA by up to 5-fold (Fig 
5.3.2F). Sox9+ cells also express K19 (another ductular progenitor marker) (Fig 5.3.2D). 
Compared with healthy control livers, cirrhotic livers accumulate up to 20-fold more Sox9/K19 
double-positive liver progenitors (Fig 5.3.2D, E). Interestingly, the highest amount of OPN is 
expressed by liver progenitors (Fig 5.3.1C – E). Double IHC confirm that OPN+ cells co-localize 
with Sox9+ cells (Fig 5.3.1C, D), and cirrhotic livers are enriched with OPN/Sox9 double positive 
progenitors by over 15-fold (Fig 5.3.1E). 
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Fig. 5.3.1: OPN is upregulated in 
human CLD and is expressed by 
Sox9+ liver progenitors 
Liver sections from patients with NASH-
cirrhosis (n = 5), ALD-cirrhosis (n = 5), 
PBC (n = 5), and excess normal donor 
livers (n = 3), were stained for OPN, and 
Sox9. OPN-staining was analyzed by 
morphometry; the number of Sox9+ cells 
(stained nuclei) was counted in 20 
randomly-chosen high-power fields 
(HPF)/section. Representative 
photomicrographs are shown. (A) OPN 
staining and OPN morphometry. (B) Sox9 
staining and Sox9 morphometry. (C) 
Sox9 (Brown) and OPN (Green)–double-
immunostaining. (D) High magnification of 
Sox9 / OPN–double-immunostaining in 
NASH-cirrhosis (black arrows) (x400). 
Sox9 / OPN quantification by cell 
counting; number of double positive cells 
per HPF. Results are expressed as fold 
change relative to normal liver and 
graphed as mean ± SEM. *p<0.05 vs. 
normal liver 
 
 
 
 
Fig. 5.3.2: Progressive human CLD is 
associated with upregulated fibrogenic 
markers and an enhanced liver progenitor 
response 
Excess donor (healthy) livers were stained for 
OPN, or the LPC markers, Sox9 and K19. 
Coded liver sections from patients with NASH, 
ALD, and PBC were also double stained for 
Sox9-K19. Representative photomicrographs 
are shown. (A) OPN in healthy liver. (B) Sox9 
in healthy liver (C) K19 in healthy liver. (D-E) 
Sox9 (brown) - K19 (green) double IHC with 
Sox9/K19 quantification by cell counting; 
number of double positive cells per HPF. The 
number of Sox9/K19 double positive cells was 
counted in 20 randomly-chosen HPF/section. 
Total liver RNA was also isolated from 
individuals with NASH, ALD, and PBC (n = 4 / 
group) and analyzed by qRTPCR. (F) OPN, 
TGF, and Sox9 mRNA. Mean ± SEM are 
graphed * p<0.05 vs. normal liver.  
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5.3.2. OPN regulates viability/proliferation of liver progenitors  
As the highest amounts of OPN were expressed by Sox9+ LPC in vivo (Fig 5.3.1), we evaluated 
the importance of OPN in LPC viability/proliferation. We utilized 603B cells (ductular LPCs) (14, 
87), which co-express Sox9, K19 (both markers of LPC), and OPN (Fig 5.3.3A). 603B 
supernatants contain high levels of OPN (Fig 5.3.4). Treating 603B with OPN aptamers or OPN 
neutralizing antibodies lowered OPN levels in culture supernatants (Fig. 5.3.4A, B). OPN 
aptamers reduced cell viability by 24 h, but this was most pronounced at 72 h (up to 2-fold 
reduction) when quantified by the CCK8 assay (Fig 5.3.3B). Because liver fibrosis and cirrhosis is 
associated with upregulated TGF- (Fig 5.3.2F) (and TGF- modulates progenitor-cell 
differentiation (129)), we repeated OPN neutralizing experiments under conditions of TGF- 
stimulation. OPN neutralization under pro-fibrogenic stimulation led to greater suppression of cell 
proliferation (3-fold; Fig 5.3.3C), and markedly increased 603B apoptosis, as measured by the 
caspase 3/7 assay (Fig 5.3.3D); sub-G1 analysis by FACS (detecting DNA fragmentation) 
confirmed comparable increases in 603B apoptosis (3-fold; Fig 5.3.3E-F). 
 
 
Fig. 5.3.3: OPN promotes LPC viability 
LPC were analyzed for OPN, Sox9 and K19 by 
western blot, and LPC-CM assayed using OPN 
ELISA. In separate experiments, LPC were treated 
with sham or OPN aptamers, in the presence or 
absence of TGF-. Viability/proliferation was 
assessed using the CCK8 assay, and apoptotic 
activity evaluated by caspase-3/7 activity and by 
sub-G1 analysis (A) OPN, Sox9, and K19 protein 
expression; OPN levels in 603B-CM. (B) Cell 
numbers under basal (non-TGF-) conditions; 24-72 
h. (C) Cell numbers under TGF- conditions; 24-72 h 
(solid line: sham aptamer-treated; dashed line: OPN 
aptamer-treated). Mean ± SEM (O.D) are graphed. 
(D) Caspase-3/7 under TGF- conditions; 72 h. 
Mean ± SEM (RFU) are graphed. (E) Sub-G1 
analysis under TGF- conditions; 72 h. % of cells in 
sub-G1 are graphed (F) Representative sub-G1 
histograms from sham or OPN-aptamer treated 603B 
at 72 h.  All experiments were performed in triplicate. 
*p<0.05 vs. respective baseline  
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Fig. 5.3.4: LPC secrete high levels of OPN 
Sham aptamers or OPN aptamers (or anti-OPN 
or isotype-matched control antibodies) were 
added to LPC-CM; LPC-CM was then assayed 
using the OPN ELISA kit (R&D). (A) OPN 
protein levels in LPC-CM treated with sham 
aptamers or OPN aptamers, and (B) OPN 
protein levels in 603B-CM treated with anti-
OPN antibody or isotype-matched antibody. 
Results were expressed as fold change relative 
to sham-aptamer or isotype-matched control. 
*p<0.05 vs. respective baseline  
 
 
5.3.3. OPN enhances progenitor-associated wound healing  
OPN effects on LPC 
Cumulative data suggest that liver progenitors are capable of re-programming into MF (13, 14, 
40). Therefore, we evaluated if changes in OPN levels would lead to similar alterations in 
progenitor phenotype. 603B-LPCs were treated with recombinant OPN or OPN aptamers. OPN 
neutralization led to a decrease in progenitor associated fibrogenic genes, Snail and Collagen 1I 
(Fig 5.3.5A), while upregulating epithelial genes, E-Cadherin and Id2 (Fig 5.3.5B). Increased cell-
motility and migration are key phenotypic changes that accompany EMT (13, 130). Therefore, we 
compared 603B migration in OPN neutralizing or control conditions. Migration was assessed by 
semi-quantitating the dimensions of a wound dividing the confluent monolayer 12 h after the 
scratch. OPN neutralization led to over 50% less wound healing (Fig 5.3.5C). Comparable results 
were observed in the modified cell-invasion assay (Fig 5.3.5D). OPN neutralization led to nearly 
70% fewer 603B cells invading across the insert membrane.  
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Fig. 5.3.5: OPN enhances LPC associated wound healing responses 
603B-LPC were treated with sham or OPN aptamers, in the presence of TGF- for 48 h. Cells were 
analyzed for EMT markers. (A) Snail and Collagen 1I mRNA. (B) E-cadherin and Id2 mRNA. Mean ± SEM 
were graphed. Wound healing and transmigration studies were performed using conditions described (C-
D). (C) Wound-healing under TGF-conditions at time 0 (time of scratch) and 12 h later; migration was 
quantified by measuring the distance dividing the two sides of the monolayer. Mean (% wound closure) ± 
SEM were graphed. (D) Transmigration under TGF-conditions was evaluated 24 h after seeding of cells, 
by counting crystal violet-stained cells on the underside membrane in 15 random HPF. Mean cell numbers 
± SEM were graphed. *p<0.05 vs sham aptamer. 
 
OPN is a complex molecule which consists of intracellular and extracellular/soluble OPN isoforms, 
which exhibit overlapping, but also different and opposing functions (19). OPN aptamers neutralize 
only soluble OPN isoforms. We evaluated if additional loss of intracellular OPN by RNAi might 
reproduce OPN aptamer effects on LPC phenotype. Compared with control (603B-shScr) (603B 
infected with lentiviral particles containing non-targeting scrambled shRNA), OPN knockdown 
(~50%) (603B-shOPN) was associated with a 2-3 fold reduction in cell proliferation under basal 
and TGF-conditions (Fig 5.3.6A-D), with minimal changes in LPC apoptosis. shOPN abrogated 
603B-LPC transmigration by 50% (Fig 5.3.6E), but did not affect wound healing response even 
under TGF-conditions (data not shown), thus indicating functional differences between 
extracellular and intracellular OPN.  
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Figure 5.3.6
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Fig. 5.3.6: OPN knockdown reduces LPC 
proliferation and transmigration 
603B-LPC were infected with lentiviral particles 
containing non-targeting scrambled  
shRNA (shScr) or OPN targeting shOPN (shOPN). 
Viability/proliferation, apoptosis, and 
transmigration studies were performed. (A) 
Western blot and densitometry showing OPN-
knockdown using lenti-shOPN compared with 
control lenti-shScr. Results were expressed as fold 
changes relative to shScr (B) CCK8 assay; cell 
numbers under basal and TGF- conditions; 24-72 
h (solid line: 603B-shScr cells; dashed line: 603B-
shOPN cells). Mean ± SEM (O.D) are graphed. 
(D) Caspase-3/7 under TGF- conditions; 48 h. 
Mean ± SEM (RFU) are graphed. (E) 
Transmigration under TGF-conditions was 
evaluated 24 h after seeding of cells, by cell-count 
in 15 random HPF. Results were expressed as 
fold change relative to shScr. *p<0.05 vs. shScr 
 
 
 
 
OPN modulates TGF-signaling 
Because the fibrotic liver is enriched with high levels of TGF-, we next evaluated if OPN effects 
on LPC were mediated by modulating TGF-signaling. Treating 603-LPC with TGF-led to the 
accumulation of phospho-Smad-2/3 proteins (Fig 5.3.7A, B), and to the preservation of Ski and 
SnoN (Fig 5.3.7A, B), transcriptional co-repressors which inhibit transcriptional activity of TGF--
dependent Smad-2/3-complexes under basal conditions (131). Both Smad phosphorylation and 
Ski and SnoN levels were unaffected by the addition of the sham aptamers. In contrast, treatment 
with OPN aptamers led to reduced levels of phospho-Smad-2/3 proteins (Fig 5.3.7A, B), while 
protecting Ski and SnoN from TGF--induced degradation. No changes were observed with 
Smad7 protein, another negative feedback mechanism that regulates the TGF- signal (132). To 
better define how OPN modulates TGF-signaling, we targeted (putative extracellular OPN-
receptors on progenitor cells) (133), treating 603B-LPC with CD44 neutralizing antibody, and v3 
antagonist XJ735. CD44 and v3 blockade resulted in a 30% reduction in phospho-Smad-2/3 
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expression (Fig 5.3.7C), resembling the effects of OPN neutralization with OPN aptamers. 
However, general depletion of OPN (intracellular) using shOPN (i.e. 603B-shOPN) did not repress 
phospho-Smad-2/3 expression (data not shown), implying that widespread OPN knockdown could 
only recapitulate some effects of OPN neutralization with OPN aptamers, and reinforcing the 
concept that extracellular OPN is different from intracellular OPN. 
 
 
 
 
 
Fig. 5.3.7: OPN aptamers inhibits TGF-
signaling  
603B-LPCs were treated with sham 
aptamers or OPN aptamers, in the 
presence or absence of TGF- (5ng/ml) 
for 48 h. In separate studies, 603B-LPCs 
were treated with a CD44 neutralizing 
antibody, and XJ735, a selective v3 
antagonist, in the presence of TGF- for 
48 h. At the end of experiments, protein 
was harvested and analyzed by western 
blot. (A) Representative western blot: 
phospho-Smad 2/3, SnoN, Ski, Smad 7, 
and beta-actin. (B) Protein densitometry 
for phospho-Smad 2/3, SnoN, Ski, and 
Smad 7. (C) Western blot and 
corresponding densitometry for phospho-
Smad 2/3. Results are expressed as fold 
change relative to respective baseline 
control, and graphed as mean ± SEM. 
*p<0.05 vs. baseline control  
 
. 
 
 
 
OPN effects on HSC  
Liver progenitors comprise not only of LPC (oval cell), but HSC, a fibroblast and recently 
recognized multi-potent progenitor (41). When activated, HSC undergo transition to become MF 
(40, 48). LPC and HSC are in close proximity, suggesting that both progenitor cell populations are 
capable of crosstalk. We therefore evaluated whether reduced levels of OPN in the 
microenvironment alters the ‘LPC- secretome’ that influences HSC phenotype. 603Bs were treated 
with OPN aptamers or sham aptamers, in the presence of TGF-for 48 hours; 603B-CM were 
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then harvested and added to primary HSC for 24 hours. As expected, the addition of 603B-CM to 
HSC resulted in activation of HSC by upregulating SMA and collagen 1 mRNA by 2 fold (Fig 
5.3.8A, B). HSC activation was enhanced when treated with TGF-stimulated 603B-CM. The 
addition of OPN aptamers to 603B resulted in a significantly altered secretome: CM from OPN 
aptamer-treated 603B induced a significantly attenuated fibrogenic-response in HSC (to almost 
quiescent) compared with CM obtained from sham aptamer-treated 603B, with 4-fold and 5-fold 
less SMA and collagen 11 mRNA under basal and TGF-stimulated conditions, respectively 
(Fig 5.3.8A, B). Experiments repeated using the human liver myofibroblast line (Lx2) revealed 
comparable findings: CM from OPN aptamer-treated 603B had diminished activating capacity on 
Lx2 cells (lower SMA mRNA by 40% and lower collagen 1I mRNA by 50%) (Fig 5.3.8C, D). To 
address concerns that effects on HSC could be related to residual OPN aptamers in the 603B-CM, 
we used CM obtained from 603B-shOPN (OPN knockdown) and 603B-shScr (control) cells, 
treated with or without TGF-(Fig 5.3.8A, B). Under basal conditions, CM derived from 603B-
shOPN activated primary HSC (SMA and collagen 11 mRNA) approximately 2-fold less than 
CM-603B-shScr (Fig 5.3.8A, B). These differences in CM-effects were reduced under TGF-
conditions (~1.5 fold). In a further experiment, 603B-shOPN and 603B-shScr were treated with 
either sham aptamers or OPN aptamers for 48 hours, and respective CMs collected to treat HSC. 
The addition of OPN aptamers virtually abolished HSC activation (SMA and collagen 11 mRNA 
levels were lower than untreated HSC). In aggregate, these data implicate the importance of OPN 
in modulating the LPC response.  
 
Finally, to confirm that OPN neutralization has a direct impact on HSC, we treated primary HSC 
directly with sham aptamers or OPN aptamers. OPN neutralization with OPN aptamers led to 50% 
decrease in SMA and collagen 11 mRNA under basal conditions (Fig 5.3.8E, F), but up to 4-
fold downregulation under TGF-stimulation. 
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In sum, OPN is a critical factor that modulates the LPC niche, by modulating progenitor-cell and 
HSC responses, via direct and indirect mechanisms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.8: OPN modulates LPC secretome and influences HSC activation 
603B-LPCs were treated with sham aptamers or OPN aptamers, in the presence or absence of TGF- 
(5ng/ml) for 48 h.  In a parallel experiment, OPN-knockdown 603B-LPC (603-shOPN) and control (603B-
shScr) cells were treated with sham aptamers or OPN aptamers, in the presence or absence of TGF-
603B-CM were then harvested, and added to cultures of primary HSC or Lx2 for a further 48 h. HSC or 
Lx2 RNA was harvested for QRTPCR. (A) SMA mRNA in primary HSC (B) Collagen 11 mRNA in 
primary HSC (C)  SMA mRNA in Lx2 (D) Collagen 11 mRNA in Lx2. Separately, primary HSC cultures 
were treated directly with sham aptamers or OPN aptamers, in the presence or absence of TGF- RNA 
was harvested after 48 h for QRTPCR. (E) SMA mRNA in primary HSC (F) Collagen 11 mRNA in 
primary HSC. Results are expressed as fold change relative to untreated HSC or sham aptamer-treated 
HSC, respectively, and graphed as Mean ± SEM. *p<0.05 vs. respective baseline as indicated, or vs. 
sham-aptamer-treated 603B conditions. CM: conditioned medium, -: absent, +: present 
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Figure 5.3.9
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5.3.4. OPN neutralization ameliorates the LPC response and fibrogenesis in Mice 
Accumulation of OPN+ (Sox9+) LPC in liver fibrosis (validation) 
CCl4 and MCD models 
Fibrosis: 
CCl4 and MCD-treated mice developed significant liver fibrosis (Fig 5.3.9, Fig 5.3.10). This was 
demonstrated by increased SR staining (8-fold) (Fig 5.3.9A, B) and hepatic hydroxyproline 
quantification. Collagen deposition was accompanied by the accumulation of SMA+ cells (10-
fold) (Fig 5.3.9C, D), and induction of key fibrogenic genes, SMA, Collagen 1I, and TGF-1(Fig 
5.3.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.9: OPN aptamers ameliorate fibrogenesis in CCL4 and MCD diet-treated mice 
CCL4: In one group, mice received twice-weekly injections of olive oil (control) or CCL4 for 6 weeks. In 
another group, mice receiving CCL4 were administered sham or OPN aptamers during the final week of 
CCL4. MCD: one group of mice was fed control-chow or the MCD diet for 5 weeks. Another group fed the 
MCD diet was treated with sham or OPN aptamers in the final week of dietary-challenge. Mice (n= 5/group) 
were sacrificed 24 h after final dose of aptamers, and livers analyzed. Representative staining are shown. 
(A-B) SR staining with morphometry and liver hydroxyproline measurements in CCL4-treated (A), and MCD-
fed (B) mice. (C-D) SMA immunoreactivity (black arrows) and morphometry (20x fields for analysis) in 
CCL4-treated (C), and MCD-fed (D) mice. Results were expressed as fold change relative to control mice 
and graphed as mean ± SEM. *p<0.05 vs. control mice 
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Figure 5.3.11
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Fig. 5.3.10: OPN neutralization represses 
fibrogenic genes in vivo  
Mice were treated as described in 5.3.9., and total 
liver RNA harvested for QRTPCR. CCL4: 
(A) SMA mRNA (B) Collagen 11 mRNA (C) 
TGF-mRNA. MCD: (D – F). Results are 
expressed as fold change relative to control mice 
and graphed as mean ± SEM. *p<0.05 vs. control 
mice, or as indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.11: OPN aptamers attenuate LPC 
response in CCL4-treated mice  
Mice were treated as described in Figure 5.3.9. 
Livers were harvested for IHC. Representative 
staining displayed. (A) OPN staining and OPN 
quantification; (B) Sox9 staining and Sox9 
quantification; % of positive cells per HPF. (C) 
Double IHC for Sox9 (Brown) and OPN (Green). 
(Bottom left panel) Sox9 / OPN double staining in 
control mice. (Top left panel) Sox9 / OPN double 
staining (accumulation of Sox9 / OPN double 
staining) in CCL4 treated mice receiving sham 
aptamers. (Top right panel) Sox9 / OPN double 
staining (loss of OPN staining) in CCL4 treated 
mice receiving OPN aptamers. (Bottom right) 
Sox9 / OPN quantification by cell counting; 
number of double positive cells per HPF. Results 
are expressed as fold change relative to control 
mice and graphed as mean ± SEM. *p<0.05 vs. 
control mice. Black arrows indicate Sox9 positive 
cells which co-express (or should co-express) 
OPN. 
 
 
 
 
- 91 - 
A
B
Figure 5.3.12
S
o
x
9
Sham Aptamers OPN Aptamers
O
P
N
S
o
x
9
+
 c
e
ll
s
 /
 %
 H
P
F
F
o
ld
 c
h
a
n
g
e
*
*
*
Sox9 - brown / 
OPN - green 
x40
Sham Aptamers OPN Aptamers
0
1
2
3
4
5
6
7
8
Control MCD +
Sham
Apt
MCD +
OPN
Apt
O
p
n
 M
o
rp
h
o
m
e
tr
y
 /
 %
 H
P
F
F
o
ld
 c
h
a
n
g
e
*
*
*
Sox9+ cells lose OPN stainSox9+ cells accumulate OPN
MCD + OPN AptMCD + Sham Apt
S
o
x
9
 +
 /
 O
P
N
 +
 c
e
ll
s
F
o
ld
 c
h
a
n
g
e
C
*
*
*
 
Figure 5.3.13
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Fig. 5.3.12: OPN aptamers attenuate LPC 
response in MCD diet-fed mice 
Mice were fed control chow or the MCD diet for 5 
weeks, in the presence of sham or OPN 
aptamers, as described in Figure 5.3.9. Livers 
were harvested for IHC. Representative staining 
are shown. (A) OPN staining and OPN 
quantification by morphometric analysis. (B) Sox9 
staining and Sox9 quantification by cell counting; 
% of positive cells per HPF. (C) Sox9 (Brown) and 
OPN (Green) – double IHC (magnification x400). 
(Left panel) Accumulation of Sox9 / OPN double 
positive cells in MCD-fed mice receiving sham 
aptamers; (Right panel) Fewer Sox9 / OPN double 
positive cells in MCD-fed mice receiving OPN 
aptamers. Graph shows Sox9 / OPN quantification 
by cell counting; number of double positive cells 
per HPF. Results are expressed as fold change 
relative to control mice and graphed as mean ± 
SEM. *p<0.05 vs. control mice. Black arrows 
indicate Sox9 positive cells which co-express (or 
should co-express) OPN. 
 
 
Liver progenitors: 
Liver fibrosis was associated with a 6-10 fold increase in OPN+ cells (Fig 5.3.11A, 5.3.12A), and 
an exuberant progenitor-response: 5-fold more Sox9+ LPC (Fig 5.3.11B, 5.3.12B), 4-fold more 
Sox9 mRNA (Fig 5.3.13A, C), and ~2-fold more K19 mRNA (Fig 5.3.13B, D).  Specifically, there 
was a 5 to 10-fold enrichment of OPN+ cells which co-expressed Sox9, the LPC marker (Fig 
5.3.11C, Fig 5.3.12C).  
 
 
Fig. 5.3.13: OPN aptamers repress Sox9 
and K19 mRNA in CCL4-treated and MCD 
diet-fed mice 
Mice were treated as described in Figure 5.3.9   
(A-B) CCL4: Sox9 and K19 mRNA. (C-D) MCD: 
Sox9 and K19 mRNA.  Results are expressed 
as fold change relative to control-treated mice 
and graphed as Mean ± SEM. *p<0.05 vs. 
control mice, or as indicated. 
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Liver progenitor re-programming: 
Liver fibrosis was accompanied by the upregulation of mesenchymal markers, OPN and Snail (Fig 
5.3.14A, B; Fig 5.3.15A, B), and a downregulation of epithelial markers, E-cadherin and Id2 (Fig 
5.3.14C, D; Fig 5.3.15C, D). Double IHC identified Sox9+ LPC which co-expressed E-Cadherin 
(Fig 5.3.14E, F; Fig 5.3.15E, F) under basal conditions; expression of E-Cadherin was 
significantly repressed during fibrogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.3.14: OPN aptamers upregulate epithelial and repress mesenchymal genes in CCL4-treated 
mice 
Mice were treated as described in Figure 5.3.9 (A) OPN mRNA. (B) Snail mRNA. (C) E-Cadherin mRNA. 
(D) Id2 mRNA. Results were expressed as fold change relative to control-treated mice and graphed as 
mean ± SEM. Livers were stained for Sox9 (Brown) and E-Cadherin (Green) (E-F).  (E) (Top left) Sox9/E-
Cadherin double-staining in control mice; (Top right) Loss of E-Cadherin staining in CCL4 mice with sham 
aptamers; (Bottom left) Re-expression of E-Cadherin in Sox9+ cells in OPN aptamer-treated mice; (Bottom 
right) Re-expression of membranous-E-Cadherin in OPN-aptamer-treated mice. (F) Sox9/E-Cadherin 
quantification by cell counting; number of double positive cells/HPF. Results are expressed as fold change 
relative to control mice and graphed as mean ± SEM. *p<0.05 vs. control mice. Black arrows indicate Sox9 
positive cells which co-express (or should co-express) E-Cadherin. White arrows indicate membranous-
expression of E-Cadherin. 
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Figure 5.3.15
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Figure 5.3.15: OPN aptamers upregulate epithelial and repress mesenchymal genes in MCD diet-fed 
mice 
Mice were treated as described in Figure 5.3.9. (A) OPN mRNA. (B) Snail mRNA. (C) E-Cadherin mRNA. 
(D) Id2 mRNA. Results were expressed as fold change relative to control-treated mice and graphed as 
mean ± SEM. *p<0.05 vs. control mice. Livers were stained for Sox9 (Brown) and E-Cadherin (Green) (E-
F).  (E) (Top) Sox9 / E-Cadherin double staining (loss of E-Cadherin staining) in sham aptamer-treated 
mice; (Bottom left) Re-expression of E-Cadherin in Sox9+ cells in OPN aptamer treated mice; (Bottom 
right) Re-expression of membranous-E-Cadherin in OPN aptamer-treated mice. (F) Sox9 / E-Cadherin 
quantification by cell counting; number of double positive cells per HPF. Results are expressed as fold 
change relative to control mice and graphed as mean ± SEM. *p<0.05 vs. control mice. Black arrows 
indicate Sox9 positive cells which co-express (or should co-express) E-Cadherin. White arrows indicate 
membranous expression of E-Cadherin 
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DDC model: 
Biliary-type fibrosis was induced by the DDC-supplemented diet (81). Increased SR staining and 
liver hydroxyproline content (Fig 5.3.16A) was similarly associated with a greater than 10-fold 
enrichment in the number of SMA+ cells (Fig 5.3.16B) and an upregulation in SMA, Collagen 
1I, and TGF-1mRNA(Fig 5.3.16C – E). There was an accumulation of OPN+ and Sox9+ cells 
(over 10-fold) (Fig 5.3.17A, B), and OPN/Sox9 double-positive cells (up to 6-fold) (Fig 5.3.17C). 
These changes were accompanied by upregulation in OPN (~14-fold) (Fig 5.3.17D), and Sox9 
mRNA (~40% increase) (Fig 5.3.17E). 
 
 
 
Fig. 5.3.16: OPN aptamers attenuate 
fibrogenesis in DDC-fed mice 
Mice were fed control chow or the DDC-diet for 
3 weeks to induce biliary-type fibrosis (n= 10; 
5/group). Another group of mice which received 
DDC-diet were injected with sham aptamers or 
OPNaptamers by tail-vein injections (4 injections 
/ mouse) in the final week of DDC treatment. 
Mice were sacrificed 24 h after final dose of 
aptamers, and livers harvested for IHC, 
QRTPCR, and the hydroxyproline assay. (A) 
Representative SR staining with corresponding 
quantification by morphometric analysis and the 
hepatic hydroxyproline assay (B) 
Representative SMA staining and 
morphometry (20x fields for analysis). (C) SMA 
mRNA (D) Collagen 1I mRNA. (E) TGF-
mRNA. Results were expressed as fold 
change relative to control-treated mice and 
graphed as mean ± SEM. *p<0.05 vs. control 
mice, or as indicated. 
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Fig. 5.3.17: OPN aptamers inhibits the LPC 
response in DDC-fed mice 
Mice were fed control chow or the DDC-diet, 
as described in 5.3.16. Livers were harvested 
for IHC and QRTPCR. Representative 
staining are shown. (A) OPN staining and 
OPN quantification by morphometric analysis. 
(B) Sox9 staining and Sox9 quantification by 
cell counting; % of positive cells per HPF. (C) 
Morphometric analysis of Sox9-OPN double-
staining. (D) Sox9 mRNA. (E) OPN mRNA. 
Results are expressed as fold change relative 
to control mice and graphed as mean ± SEM. 
*p<0.05 vs. control mice, or as indicated.  
 
 
 
 
 
 
OPN neutralization attenuates the LPC response and ameliorates fibrogenesis (interventional) 
CCl4 and MCD models 
Fibrosis: 
Aptamers were administered during the final week of liver injury. No mice died. OPN neutralization 
ameliorated liver fibrosis in both CCl4-treated, and MCD-fed mice. OPN aptamers significantly 
repressed hepatic hydroxyproline content and the amount of SR-stained fibrils (Fig 5.3.9A, B) by 
4-5 fold, reduced SMA+ cells by 50-80% (Fig 5.3.9C, D), and downregulated SMA (80-90%), 
Collagen 1I (50-100%), and TGF-1 (50-90%) mRNA (Fig 5.3.10). 
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Liver progenitors: 
Inhibited fibrogenesis was accompanied by fewer liver progenitors (Fig 5.3.11, Fig 5.3.12, Fig 
5.3.13). OPN+ cells and Sox9+ cells were ~4-fold and ~2-3-fold fewer, respectively, after OPN-
neutralization (Fig 5.3.11A, B; Fig 5.3.12A, B). There was parallel repression of Sox9 and K19 
mRNA levels (Fig 5.3.13).  
 
Liver progenitor re-programming: 
OPN-neutralization also downregulated mesenchymal markers, OPN and Snail (Fig 5.3.14A, B; 
Fig 5.3.15A, B) while upregulating epithelial markers, E-cadherin and Id2 (Fig 5.3.14C, D; Fig 
5.3.15C, D). Immunostaining further revealed the restored-expression of membranous-E-
Cadherin, and greater number of Sox9/E-Cadherin double-positive cells in OPN aptamer-treated 
mice, to near normal levels (Fig 5.3.14E, F; Fig 5.3.15E, F). This was mirrored by a reduction in 
Sox9/OPN double positive cells to basal levels (Fig 5.3.11C; Fig 5.3.12C), thus confirming 
reversal of the fibrogenic phenotype. 
 
DDC model: 
Comparable outcomes were noted in DDC-fed mice: OPN aptamer treatment led to ~4 fold less 
hepatic hydroxyproline, ~2-fold less SR stained fibrils (Fig 5.3.16A), ~3-fold fewer SMA+ cells 
(Fig 5.3.16B), and repression of SMA (3-fold), Collagen 1I (~25%), and TGF-(~30%) mRNA 
(Fig 5.3.16C – E). This was accompanied by an attenuated LPC response: fewer OPN+ (~4-fold) 
(Fig 5.3.17A), Sox9+ (~3-fold) (Fig 5.3.17B), and Sox9/OPN double positive cells (~2-fold) (Fig 
5.3.17C). There was a comparable downregulation in OPN (3-fold), and Sox9 (2.5-fold) mRNA 
(Fig 5.3.17D, E). By contrast, Sox9/E-Cadherin double positive cells increased nearly 2-fold (Fig 
5.3.18) during OPN-neutralization. 
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Fig. 5.3.18: OPN aptamers upregulate E-
Cadherin in DDC-fed mice 
Mice were treated as described in 5.3.16. 
Livers were stained for Sox9 (Brown) and 
E-Cadherin (Green). (A) Loss of E-
Cadherin staining in DDC-fed mice with 
sham aptamers, and upregulation of E-
Cadherin in Sox9+ cells in OPN aptamer-
treated mice. (B) Sox9/E-Cadherin 
quantification by cell counting; number of 
double positive cells/HPF. Results are 
expressed as fold change relative to 
control mice and graphed as mean ± SEM. 
*p<0.05 vs. control mice. Black arrows 
indicate Sox9 positive cells which co-
express (or should co-express) E-
Cadherin.  
 
The outcomes of OPN aptamer-studies were verified using OPN neutralizing antibodies. MCD-fed 
mice that received OPN antibodies accumulated 4-5 fold less SR-stained fibrils (Fig 5.3.19A), 
60% fewer SMA+ cells (Fig 5.3.19B), and downregulated SMA, Collagen 1I, TGF-1 mRNA 
by up to 60% (Fig 5.3.19C – E). This was associated with fewer OPN+ and Sox9+ cells (~80%) 
(Fig 5.3.20A, B), and reduced OPN and Sox9 mRNA (~50%) (Fig 5.3.20C, D). 
 
 
Fig. 5.3.19: OPN neutralizing antibodies inhibit 
fibrogenesis in MCD diet-fed mice 
To verify results of aptamer studies, a further study 
was performed using OPN neutralizing antibodies. 
MCD diet-fed mice (n= 10; 5/group) were injected 
either control (IgG) or anti OPN in the final week, as 
described in Methods (i.e. 4 injections via tail-vein 
injections per mouse; 50ug per injection). Mice were 
sacrificed 24 h after the final injection, and livers 
harvested for IHC and QRTPCR. (A) Representative 
Sirius Red staining and quantification by morphometric 
analysis. (B) Representative SMA staining and SMA 
morphometry (20x fields chosen for analysis by the 
Metaview software). Black arrows denote cells 
expressing respective antigens. (C) SMA mRNA. (B) 
Collagen 1I mRNA. (C) TGF-mRNA. Results were 
expressed as fold change relative to IgG-treated mice 
and graphed as mean ± SEM. *p<0.05 vs. IgG-treated 
mice 
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Fig. 5.3.20: OPN neutralizing antibodies attenuate 
the LPC response in MCD diet-fed mice 
MCD diet-fed mice were injected either control (IgG) 
or anti-OPN as described in 5.3.19. Livers were 
harvested for IHC and QRTPCR. (A) Sox9 staining 
and Sox9 quantification by cell counting; % of positive 
cells per HPF. (B) Representative OPN staining and 
morphometric analysis (20x fields chosen for analysis 
by the Metaview software). (C) OPN mRNA. (D) Sox9 
mRNA. Results were expressed as fold change 
relative to IgG-treated mice and graphed as mean ± 
SEM. *p<0.05 vs. IgG-treated mice. Black arrows 
denote cells expressing respective antigens. 
 
 
 
 
 
In summary, targeting OPN using two neutralizing approaches, and in three liver disease models, 
led to an attenuated liver progenitor-cell response, and an amelioration of murine liver fibrosis. 
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5.4. Role of OPN in Liver Inflammation 
 
NKT associated OPN drive fibrogenesis in NAFLD  
(Syn WK et al. Gut. 2012 Sep; 61(9):1323-9) 
 
 
The liver contains a large number of NKT cells, which provide intravascular immune surveillance 
(134, 135). NKT cells respond to glycolipid antigens presented by MHC class 1-like molecule, 
CD1d, and when activated, secrete both Th1 (pro-inflammatory / anti-fibrotic) and Th2 (anti-
inflammatory / pro-fibrotic) cytokines (135 – 138). In the hepatitis B virus-transgenic mouse (139), 
NKT-derived IL4 and IL13 were reported to be responsible for the fibrogenic outcomes. 
Conversely, CD1d knockout (CD1d-/-) mice, which lack NKT cells, were protected from xenobiotic-
induced hepatic inflammation, injury and fibrosis (140). These findings complement human studies 
showing NKT accumulation in primary biliary cirrhosis (141, 142) and chronic viral hepatitis C 
(143). 
 
The role of NKT cells in NAFLD progression is only beginning to emerge. NKT cells are generally 
depleted in fatty livers (144 – 146), but appear to accumulate in livers with NASH-related fibrosis 
(146, 147). Recently, we reported that Hh mediated accumulation of NKT cells contributes to 
development and progression of NASH in mice and humans (16). Mice with an overly active Hh 
pathway express higher levels of the NKT cell chemokine, CXCL16, the adhesion molecule 
VCAM-1, and IL15, a factor that promotes NKT viability (148). These mice accumulate more 
hepatic NKT cells, and develop worse NASH fibrosis. Consistent with this, we found that 
individuals with NASH-cirrhosis harbored 4 fold more NKT cells than those with healthy livers.  
 
In addition to secreting the classical cytokines, IL4 and IL13, NKT cells can also secrete OPN, a 
cytokine and matricellular protein that exacerbates Concavalin A induced hepatitis (24), and 
promotes NAFLD progression (Results: 5.1). Recently, we showed that NKT cells also secrete 
the fetal morphogen, Shh (17). Shh induces the transition of quiescent HSC into activated, 
collagen-producing MF (48), and amplifies the ‘repair-associated inflammatory response’ (15). 
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Intriguingly, inhibition of the Hh pathway in vivo leads to the amelioration of fibrosis in mice with 
cholestatic liver injury (149).  
 
In this study, we evaluated the hypothesis that fibrosis progression in NASH is NKT cell-
dependent. We fed mice that were genetically deficient in NKT cells (J18-/- and CD1d-/-) MCD 
diets to induce NASH, evaluated if NKT depletion protected against NASH fibrosis, and assessed 
if NKT cell-mediated fibrogenesis required OPN. Findings in mice and cultured HSC were then 
corroborated by evaluating similar endpoints in patients with NASH.   
 
5.4.1. NKT-deficient mice develop less fibrosis than WT mice after MCD diets 
Compared to WT mice that were fed normal chow (n= 10), MCD diet-treated mice (n= 10) 
developed significant steatohepatitis and fibrosis after 8 weeks (Fig 5.4.1A).  The latter was 
demonstrated by increased SR staining (Fig 5.4.1B, C), and hepatic hydroxyproline quantification 
(Fig 5.4.1D). Collagen deposition was accompanied by the accumulation of SMA-
immunoreactive cells (Fig 5.4.2A, B), and induction of pro-fibrogenic genes, including -sma, 
collagen , and TGF(Fig 5.4.2C, D;  Fig 5.4.3A).  
 
 
 
 
 
Fig. 5.4.1: NKT-deficient mice develop less fibrosis 
after the MCD diet 
WT, J18-/- and CD1d-/- mice were fed control chow (n= 
10/strain) or MCD diet (n= 10/strain) for 8 weeks, and 
then sacrificed. (A) Representative H&E and (B) SR 
staining after MCD diet. (C) SR quantification by 
morphometric analysis; results are expressed as fold 
change relative to WT control chow-fed mice, and 
graphed as mean ± SEM. (D) Hepatic hydroxyproline 
content at the end of the treatment period. *P<0.05 vs. 
control chow-fed mice.  
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Fig. 5.4.2: NKT-deficient mice exhibit attenuated 
fibrogenic response compared with WT mice 
Mice were fed control chow and MCD diets as 
described in 5.4.1. (A) SMA immunoreactivity and (B) 
SMA morphometry. Sections from 4 animals were 
used and 15 randomly selected, 20x fields chosen for 
analysis by the Metaview software. Small inserts in (A) 
show representative staining from chow-fed mice. 
Whole liver tissues were harvested for RNA analysis by 
QRTPCR. (C) SMA mRNA, (D) Collagen I1 mRNA, 
and (E) ALT IU/L. Results are expressed as fold 
change relative to WT control chow-fed mice and 
graphed as mean ± SEM. *P<0.05 vs. control chow-fed 
mice 
 
 
 
 
 
 
Fig. 5.4.3: NKT-deficient mice exhibit 
reduced TGF- and attenuated Hh 
signaling after MCD diet induced NASH. 
Mice were fed control chow and MCD diets 
as described in 5.4.1. Whole liver tissue 
was harvested for RNA analysis by 
QRTPCR. (A) TGF, (B) Indian Hedgehog 
(Inh), (C) Gli2 mRNA. Results are 
expressed as fold change relative to WT 
control chow-fed mice and graphed as 
mean ± SEM. *P<0.05 vs. WT control chow-
fed mice 
 
 
 
J18-/- mice which lack invariant NKT cells, developed significantly less hepatic fibrosis (Fig 
5.4.1B – D; Fig 5.4.2A – D) and injury (Fig 5.4.2E) than WT mice after MCD diet. This finding in 
mice that lack invariant NKT cells is consistent with our previous report that CD1d-/- mice (which 
lack all NKT subsets) exhibited reduced fibrogenic responses after diet induced NASH (16) (Fig 
5.4.1C, D; Fig 5.4.2B – D; Fig 5.4.3A). 
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We reported that Hh pathway activation induces the transition of quiescent HSC to collagen-
producing MF (48), and promotes fibrogenic repair in NASH (14). Consistent with this, Indian Hh 
(a Hh ligand), and Gli2 (a Hh-regulated transcription factor) were significantly induced during diet-
induced NASH (Fig 5.4.3B, C). Conversely, NKT-deficient mice, which developed less fibrosis, 
exhibited attenuated Hh signaling (Fig 5.4.3B, C). 
 
5.4.2. NKT-deficient mice express less OPN during MCD diet-induced NASH than WT mice 
In Result Section 5.1, we showed that OPN acts in paracrine and autocrine fashions to promote 
HSC activation and fibrogenesis. After MCD diet, OPN-/- mice exhibited reduced fibrosis, while 
mice that overexpressed OPN developed worse fibrosis. Here, we show that livers from MCD fed 
WT mice upregulate OPN protein expression by nearly 5 fold (Fig 5.4.4A, C). In contrast, livers of 
both NKT cell deficient strains that developed less fibrosis than WT mice after diet-induced NASH 
had significantly reduced levels of OPN (Fig 5.4.4A, C; Fig 5.4.5).  These findings raise the 
possibility that NKT cell associated factors modulate OPN expression and resultant liver fibrosis. 
 
 
 
Fig. 5.4.4: NKT-deficient mice harbor less liver and 
plasma OPN than WT mice after MCD diet-induced 
NASH 
Mice were fed as described in 5.4.1. Matched plasma 
was collected for OPN ELISA. (A-C) Representative 
OPN immunostaining after control chow or MCD diets in 
WT and J18-/- mice (final magnification 200X), and 
quantification by morphometry. Sections from 10 
animals were used per group and 10 randomly selected, 
200X fields chosen for analysis by the Metaview 
software. Results are expressed as fold change (% 
positive staining) relative to WT control mice, and 
graphed as mean ± SEM. (D) Plasma OPN. Plasma 
from 10 animals per group were used for OPN ELISA, 
and displayed as pg/ml. Each sample was run in 
duplicate. *P<0.05 vs. WT control mice 
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Figure 5.4.5
 
 
 
 
Fig. 5.4.5: Livers from NKT-deficient mice 
contain less OPN than WT mice after MCD 
diet. 
Mice were fed as described in 5.4.1. (A) 
Representative OPN immunostaining after 
control chow or MCD diets in CD1d-/- mice 
(final magnification 200X). Whole liver RNA 
was analyzed by QRTPCR. (B) OPN mRNA. 
Results are expressed as fold change relative 
to WT control chow-fed mice and graphed as 
mean ± SEM. *P<0.05 vs. WT control chow-
fed mice 
 
 
 
Previously, others reported that plasma OPN levels correlated with severity of liver fibrosis in 
subjects with chronic hepatitis B and C (150, 151). In this study, plasma from WT mice with NASH 
fibrosis contained nearly 2 fold more OPN by ELISA than chow fed controls (Fig 5.4.4D). 
Consistent with reduced hepatic OPN expression, plasma OPN levels were 2 fold lower in NKT 
cell deficient mice after diet-induced NASH. The aggregate data, therefore, suggest that elevated 
plasma OPN levels may be a biomarker of advanced NASH fibrosis. 
 
5.4.3. Primary mouse liver NKT cell associated OPN promotes MF activation of primary HSC  
In addition to HSC and cholangiocytes (Results: 5.1 and 5.3), OPN is expressed by activated 
immune cells (24). Therefore, we examined if activated liver NKT cells generate OPN that acts in a 
paracrine fashion to promote HSC fibrogenesis. Primary LMNC were isolated from healthy mice 
and incubated with GC (which specifically activates iNKT cells) or vehicle overnight; LMNC-CM 
was then collected for OPN ELISA. GC-activated LMNC-CM contained 4 fold more OPN protein 
than vehicle treated LMNC-CM, and similar levels of OPN as CM from cholangiocytes, which are 
known to be a source of OPN in liver (Fig 5.4.6A). To ascertain if activated LMNC in vivo also 
express higher amounts of OPN, we harvested primary LMNC from chow or MCD fed WT mice 
(n=4/group), and OPN expression was analyzed by QRTPCR. Primary LMNC from MCD fed mice 
harbored 12 fold more OPN mRNA than LMNC from chow fed mice (Fig 5.4.6B). GC-activated 
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LMNC-CM was then added to primary cultures of mouse HSC with either OPN aptamers or sham 
aptamers for 48 h. The addition of OPN aptamers to neutralize OPN activity in LMNC-CM resulted 
in a significant repression of HSC fibrogenic genes (OPN, Collagen) (Fig 5.4.6C, D).  
 
To ascertain if differences in the fibrogenic outcomes observed in Fig 5.4.1 could be attributed to 
fewer NKT cells, and hence, reduced NKT derived OPN, we isolated primary LMNC from WT, 
J18-/- and CD1d-/- mice, and incubated them with GC or vehicle overnight, and LMNC-CM was 
collected for OPN ELISA, or added to primary cultures of HSC. We found that WT-LMNC mice 
secreted 5 fold more OPN protein (Fig 5.4.6E) and induced greater collagen expression in HSC 
than NKT deficient-LMNC (Figure 5.4.6F). These findings, in concert, support the hypothesis that 
activated NKT cell associated OPN promotes HSC activation in a paracrine fashion.  
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Fig. 5.4.6: GC-activated liver NKT cell associated OPN promotes HSC activation 
Primary LMNC (1 x 105) from WT mice were cultured in complete NKT media, and treated with vehicle (V) 
or GC (to activate NKT cells) for 24 h.  CM was collected for OPN ELISA; 603B mouse cholangiocyte-CM 
was used as a positive control. (A) OPN protein was quantified by ELISA.  Each LMNC-CM sample was run 
in duplicate and expressed as pg/ml. (B) LMNC were isolated from WT mice that were fed control chow (n= 
4) or MCD diet (n= 4) for 8 weeks, and OPN mRNA expression was analyzed by QRTPCR. Results are 
expressed as fold change relative to control chow derived LMNC. (C-D) Mouse primary HSC were cultured 
with CM from GC-activated WT LMNC(GC-CM) + OPN aptamers or sham aptamers for  48 h; HSC 
expression of collagen I 1(C) and OPN (D) mRNA were assessed by QRTPCR. Results are expressed as 
fold change relative to HSC that were treated with CM from vehicle-treated WT LMNC (V-CM).  (E) OPN 
was quantified by ELISA in CM from LMNC that were harvested from WT, J18-/- or CD1d-/-mice and 
treated with either vehicle (V) or GC to activate NKT cells.  Results are expressed as fold change relative 
to vehicle (V)-treated WT LMNC. Mouse primary HSC were cultured for 48 h in LMNC-CM harvested from 
WT, J18-/-, and CD1d-/- mice and treated with vehicle or GC to activate NKT cells. HSC expression of 
collagen I 1 mRNA was assessed by QRT PCR (F). Results are expressed as fold change relative to HSC 
that were cultured with CM from respective vehicle-activated LMNC. Mean ± SEM of duplicate experiments 
are graphed. *P<0.05 
 
 
5.4.4. NASH progression in humans in accompanied by increased liver and plasma OPN 
Herein, we demonstrate that fibrogenesis in mice with diet-induced NASH depends upon hepatic 
NKT cells, and show the mechanism involves NKT cell-mediated production of OPN. As NKT cells 
comprise a much greater proportion of the resident hepatic immune cells in mice than humans 
(152, 153), we next examined livers from patients with NASH to assess the relationship between 
hepatic NKT cell accumulation, OPN expression, and fibrosis in humans.  
 
Human livers with advanced NASH (stage 3-4 fibrosis) contained 3 fold more OPN, particularly in 
the fibrous septa, than those with early NASH (no fibrosis or stage 1-2 fibrosis) (Fig 5.4.7A, B). 
Previously, we reported that the hepatic content of cells that co-express CD57 and CD3 or CD56 
and CD3 (i.e., NKT cells) is increased significantly in patients with NASH-related cirrhosis (16). 
Here we show that NKT cells that accumulate during NASH fibrosis express OPN protein (Fig. 
5.4.8A – C). Moreover, we found that increased hepatic OPN expression was mirrored by higher 
plasma OPN levels in NASH patients with advanced fibrosis than those with mild fibrosis (Fig 
5.4.7C). Overall plasma OPN levels in NASH were approximately 2 fold higher than levels 
detected in healthy volunteers (mean OPN level, normal: 3000pg/ml) (150). The findings in 
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humans with NASH, therefore, are similar to those in mice with NASH and together suggest that 
OPN may be a useful biomarker of advanced NASH fibrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.4.7: NASH progression in humans is accompanied by upregulation of liver and plasma OPN 
(A-B) Coded liver sections from 10 patients with early and advanced NASH fibrosis were stained for OPN, 
and OPN expression was quantified by computer-assisted morphometry. (A) Representative 
photomicrographs from patients with early and advanced NASH fibrosis. (B) Quantitative analysis of liver 
OPN positive cells in all patients. Numbers of OPN positive cells are expressed as percentage of stained 
cells per high-powered field. (C) Plasma was collected from individuals with early or advanced NASH 
(n=25/group) and plasma OPN measured by ELISA. Plasma samples were run in duplicate. Mean ± SEM 
are graphed; * p<0.001 vs early fibrosis. 
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Fig. 5.4.8: NASH progression in humans is associated with the accumulation of OPN expressing 
NKT cells 
Coded liver sections from patients with NASH fibrosis were double stained for CD57 / OPN. LMNC from a 
non-diseased liver were stained for CD3, CD56, OPN, and analyzed by FACS analysis. (A) CD57 (brown) – 
OPN (blue) double staining. (B) CD3-CD56 double positive NKT cells, (C) Proportion of CD3-CD56 NKT 
cells which expressed intracellular OPN 
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Chapter 6 
 
Osteopontin is induced by Hedgehog Pathway Activation and Promotes Fibrosis 
Progression in Nonalcoholic Steatohepatitis  
(Syn WK et al. Hepatology. 2011 Jan; 53(1):106-15.) 
 
Previously, we demonstrated that dying hepatocytes produce Hh ligands (11, 12), which engage 
various types of Hh-responsive cells, including HSC, ductular cells / LPCs, and NKT cells, to 
trigger fibrogenic responses (13, 14, 17). We observed that Hh pathway activity correlated with MF 
accumulation and fibrosis stage in NAFLD patients and rodent models of NAFLD, and suggested 
that inter-individual differences in Hh signaling influenced intensity of fibrogenic responses during 
NASH (14). The present studies provide further support for this concept because they identify 
OPN as a proximal effector of Hh mediated fibrogenesis, and demonstrate that livers of OPN-/- 
mice are significantly protected from NASH fibrosis.   
 
A recent analysis of the OPN gene revealed binding sites for Gli transcription factors, suggesting 
that OPN transcription is likely to be regulated by Hh signaling (18). By demonstrating co-
localization of Gli and OPN in liver cells, and proving that expression of OPN mRNA is increased 
by a Smoothened agonist, but decreased by a Smoothened antagonist, our results support and 
advance this concept. In addition, our data demonstrate that changes in OPN gene expression are 
paralleled by changes in OPN protein content and biological activity because OPN aptamers 
reverse the pro-fibrogenic actions of OPN. The latter studies also verify that OPN is a significant 
downstream target of Hh signaling (rather than vice versa) because neutralizing OPN had no 
effect on cellular expression of the Hh target, Gli2, but significantly diminished  fibrogenic gene 
expression, even in Ptc+/- cells with supra-normal Hh pathway activity. Coupled with the evidence 
that OPN-/- mice are significantly protected from NASH fibrosis, the data explain why we noted 
that hepatic content of Gli2(+) cells and OPN (+) cells increased in parallel as liver fibrosis 
advanced in patients with NAFLD.  
 
OPN may also dictate the fibrogenic response in other chronic liver diseases, as it is significantly 
overexpressed in livers from cirrhotic ALD, AIH, PBC and PSC, and a recent study reported that 
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plasma OPN levels correlate with hepatic inflammation and fibrosis in chronic hepatitis C (151).  
Although more work is needed to delineate the interactions between OPN and other putative pro-
fibrogenic factors (81), this concept suggests that OPN levels may provide a useful biomarker for 
liver fibrosis in NASH, and that OPN neutralization might be useful for preventing progressive 
hepatic fibrosis in NASH patients.  
 
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) 
fibrosis  
(Coombes JD ….Syn WK. Biochim Biophys Acta. 2016 Jan; 1862(1):135-44) 
 
OPN is an important downstream effector of leptin-induced fibrogenesis. The loss of OPN using 
OPN aptamers or OPN knockdown abrogates HSC activation despite the presence of exogenous 
leptin, and these in vitro observations were recapitulated in the ex vivo liver slice model. These 
results are consistent with findings from studies on Hh signaling in liver fibrosis. Both OPN and Hh 
are leptin regulated, and are key effectors of leptin-induced liver fibrosis. An over-activation of the 
Hh pathway leads to tissue fibrosis and cancer, while the loss of Hh signaling impairs wound 
healing (i.e. less fibrosis) (154, 155). In the liver, we and others recently reported that over-
activation of the Hh pathway occurs during human NASH progression (14), and that blocking Hh 
with the commercially available inhibitor, GDC0449 or cyclopamine ameliorates NASH and 
reduces liver fibrosis in mice (156).  
 
The prevalence of NAFLD and NASH is increasing in parallel with the rising tide of obesity and 
type 2 diabetes mellitus. Studies show that obese individuals and those who harbour additional 
metabolic risk factors are at a much higher risk of developing NASH and /or NASH fibrosis (157). 
Therefore, targeting ‘modifiable’ mediators in these ‘at-risk’ individuals could help alleviate NASH / 
fibrosis burden. Leptin is an adipose tissue-derived hormone whose physiological role is to induce 
satiety, but levels of leptin are significantly higher in the obese, and in some with NAFLD (110, 
111). To date, studies have evaluated the potential utility of leptin replacement in those with 
hypoleptinemia-NASH. In one study, leptin administration improved steatosis, but not fibrosis 
stage (158), and as leptin is directly pro-fibrogenic, it is possible that supplementation of 
- 113 - 
exogenous leptin may inadvertently lead to worsening fibrosis. On the other hand, leptin 
neutralization in those with advanced NASH-fibrosis (and excess leptin) may be a useful anti-
fibrotic strategy (as observed in ob/ob mice), although the likely increase in food intake and body 
weight (and metabolic risk) may well cancel out any potential clinical benefit.  
 
Like leptin, plasma OPN levels are increased in the obese and in patients with type 2 diabetes 
mellitus, hypertension, and ischemic heart disease (159). More recently, serum OPN was also 
found to be associated with the onset of diabetic nephropathy and cardiac events (160). Thus, 
high levels of OPN occur in those with the metabolic syndrome, a risk factor for progressive 
NASH. Importantly, OPN neutralization reduces infiltration of macrophages and immune subsets 
into adipose tissues, reduces obesity-induced inflammation, and improves systemic glucose 
tolerance (25, 161 – 163). In concert with the current findings, these data suggest that OPN could 
be an important target in the treatment of obese patients with NASH (and the metabolic 
syndrome), by reducing insulin resistance and limiting NASH-fibrosis (in spite of high prevailing 
leptin levels).  
 
In summary,  our analyses show that OPN is leptin-regulated, and is a key effector of leptin-
induced, NASH fibrosis. Future studies will be necessary to evaluate the utility of OPN 
neutralization in various models of obesogenic NASH (such as the high-fat, high fructose / 
sucrose-fed model), and evaluate if extended periods of treatment could lead to even better anti-
fibrotic outcomes.  
 
Osteopontin Neutralization Abrogates the Liver Progenitor Cell Response and Fibrogenesis 
in Mice  
(Coombes JD …. Syn WK. Gut. 2015 Jul; 64(7):1120-31) 
 
This is the first study to show that OPN neutralization is effective in treating murine liver fibrosis. 
Treatment with OPN aptamers or OPN neutralizing antibodies attenuated the LPC response, and 
repressed fibrogenesis to levels comparable with control chow-fed mice, suggesting that one week 
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of ‘anti OPN’ treatment is safe, and effective in reversing fibrogenic outcomes. Mechanistically, we 
show that OPN is an important viability factor for LPCs, and directly regulates LPC phenotype by 
up-regulating mesenchymal genes while repressing epithelial ones. Importantly, OPN 
neutralization significantly inhibited LPC migration in wound healing and transmigration assays, 
key features of EMT (130).  
 
EMT describes the process by which epithelial progenitors acquire a more mesenchymal 
phenotype that facilitates their migration into the stroma (164). This process is critical for 
development and is characteristic of invasive cancers. Fate-mapping studies in three distinct 
mouse-strains and in two models of chronic liver injury provide compelling evidence that EMT 
occurs during liver regeneration and repair (40, 41, 165). Comparable features of EMT are 
detected in human diseased livers (13, 14). In this study, OPN neutralization led to fewer Sox9+ 
LPC, and significantly less hepatic K19 and Sox9 mRNA (i.e. attenuated liver progenitor response) 
than sham treated mice. Importantly, Sox9+ LPC lost E-Cadherin expression with fibrosis 
progression, but regained epithelial type expression during OPN neutralization. Sox9+ LPC also 
lost expression of the mesenchymal marker, OPN, during fibrosis regression. The collective in 
vitro and in vivo data support the hypothesis that OPN regulates LPC-wound healing responses. 
 
The liver progenitor niche comprises the LPC (oval cell), bone marrow-derived progenitors, and 
HSC (166). Previously, we showed that co-cultures of LPC with HSC led to enhanced progenitor 
cell proliferation and EMT (13) while LPC-derived Hh ligands and OPN activate HSC into 
myofibroblast (Result: 5.1). Here, we showed that OPN neutralization resulted in a ‘less 
fibrogenic’ LPC-secretome in vitro and a ‘less-fibrogenic’ progenitor cell microenvironment in vivo, 
highlighting the importance of OPN within the progenitor niche. This finding is particularly relevant 
given our recent study identifying HSC as a resident multi-potent progenitor (40, 41), and provides 
an explanation for their shared phenotype (i.e. LPC and HSC express similar progenitor markers, 
and undergo EMT) (14, 48). Thus, LPC and HSC interact to replenish the progenitor pool (41), and 
identify OPN as a key modulator of the LPC-associated response during injury. 
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OPN binds to multiple receptors (19). As such, it is likely that OPN neutralization has other effects, 
apart from modulating LPC and HSC responses. Preliminary studies show that OPN can promote 
immune cell entry into the liver and perpetuate hepatic injury, while others have reported that OPN 
can directly regulate immune cell functions (167). OPN and its family members are also known to 
bind to MMPs (168). Collectively, these observations explain in part, how OPN neutralization could 
lead to such impressive reversibility in fibrosis. Further studies however, will be needed to 
evaluate how OPN modulates MMP activities and whether OPN regulates specific immune subset 
recruitment and function (fibrosis-promoting vs. fibrosis-regressing) in vivo (169).  
 
TGF-is a pro-fibrogenic cytokine, and promotes progenitor-cell EMT (129). Given that OPN also 
regulates the liver progenitor-response and EMT, it is not surprising that TGF-and OPN may 
interact. Previously, we showed that TGF-mRNA expression is Hh regulated (14). In this study, 
we confirmed that OPN neutralization in mice led to reduced TGF-1 mRNA. Intriguingly, OPN 
neutralization also decreased levels of phospho-Smad-2/3-complexes in LPC. This was mirrored 
by increased Ski and SnoN, two potent transcriptional co-repressors of the TGF-pathway (131). 
Under basal conditions, Ski and SnoN inhibit gene transcription; TGF-stimulation leads to Ski 
and SnoN degradation, thereby, allowing phospho-Smad-2/3 to bind to target genes. The results 
imply that OPN may be a novel regulator of SnoN and Ski levels during fibrogenic liver repair, and 
OPN neutralization decreases levels of phospho-Smad-2/3 which, in turn, triggers proteosomal-
degradation of Ski and SnoN (170). This is consistent with observations that Ski and SnoN over-
expression are associated with amelioration of renal fibrosis, and resistance to renal-tubular EMT 
(171). Our preliminary studies further suggest that OPN mediated effects may occur via OPN-
CD44 and OPN-v3 interactions (putative OPN-receptors). The aggregate findings show that 
OPN effects are mediated in part, by modulating TGF-signaling, complementing and extending 
earlier evidence which positioned both OPN and TGF- downstream of Hh during liver 
fibrogenesis (14; Results: 5.1).  
 
- 116 - 
To date, studies have utilized OPN knockout (genetically deficient) mice (14, 81, 95). Despite their 
usefulness in providing proof-of-concept, translating findings from these animals to humans are 
limited, as genetic modifications may result in contradictory outcomes when subjected to chronic 
injury. These disparities could be explained by the presence of distinct OPN isoforms (intracellular 
and extracellular/soluble) which exhibit overlapping, but also differing functions (19). Soluble OPN 
behaves as a cytokine while intracellular OPN is an important viability and cytoskeletal protein that 
regulates intracellular protein functions. In support, our cell culture data show that the reduction of 
intracellular OPN expression (in 603B-shOPN) leads to similar but non-identical outcomes. In vivo, 
OPN knockout mice developed more fibrosis after chronic CCL4 (95), but less fibrosis in dietary-
induced NASH (14). Similar divergent outcomes have been reported in OPN knockout mice with 
lung or rheumatological disease (172, 173). OPN aptamers or OPN neutralizing antibodies used in 
this study is potentially safer because it negates the excess circulating OPN without directly 
abolishing the expression of intracellular OPN necessary for key cellular function (133). 
Furthermore, in clinical practice, individuals are more likely to need treatment for advanced-
fibrosis, as opposed to prophylactic anti-fibrotics; therefore, the administration of OPN neutralizing 
therapies once fibrosis has developed is more likely to be clinically relevant (1). 
 
Although no mice died in this study, future studies need to specifically evaluate the potential risks 
of OPN neutralization. OPN overexpression however, occurs during tissue inflammation and 
fibrosis (skin, lung, kidneys, bone marrow), and in individuals with metabolic risk factors such as 
obesity, endothelial dysfunction, and diabetes (19, 174). Thus, neutralizing and lowering excess 
extracellular OPN under such circumstances could be beneficial. This concept and therapeutic 
safety is supported by a recent phase 1/2 study of OPN-neutralization in patients with advanced 
rheumatoid arthritis (126). 
 
In summary,  our analyses in cell culture, mice and humans show that OPN upregulation during 
liver injury is a conserved repair response, and influences LPC function by modulating TGF-
signaling. OPN neutralization using two neutralizing modalities, and in three different models of 
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mice abrogated the LPC response and liver fibrosis. Future studies will be necessary to evaluate 
the importance of alternative mechanisms by which OPN modulates fibrogenesis, and to evaluate 
if extended periods of treatment could lead to even better anti-fibrotic outcomes. As humanized 
antibodies to OPN and OPN aptamers are currently being developed, future studies will also be 
needed in humans to evaluate the safety and efficacy of anti OPN treatment.  
 
NKT associated OPN drive fibrogenesis in NAFLD  
(Syn WK et al. Gut. 2012 Sep; 61(9):1323-9) 
 
This study shows that hepatic NKT cells are critical drivers of fibrogenesis in NASH, and 
demonstrates that the mechanism involves NKT cell mediated increase in the liver content of 
OPN. Importantly, plasma levels of OPN reflect the activity of this process in liver and thus, may 
prove to be a useful non-invasive marker of advanced NASH.   
 
Previously, we reported that Hh pathway activity correlates with severity of NAFLD liver injury (14), 
and showed that Hh signaling enhances hepatic accumulation of immune cells, including CD1d-
restricted NKT cells (16). Here, we prove that fibrogenesis in mice with diet-induced NASH directly 
depends upon NKT cells.  Compared with WT mice, two strains of NKT cell deficient mice (J18-/- 
and CD1d-/-) exhibited dramatically attenuated fibrosis after 8 weeks of MCD diets. NKT cell 
deficient mice also demonstrated blunted Hh pathway activity (less expression of Hh ligand and 
the Hh-regulated transcription factor, Gli2), and reduced expression of OPN, a Hh-regulated 
cytokine which acts in both paracrine and autocrine manners to promote HSC activation and 
fibrogenesis (Results 5.1).  
 
In the present study, LMNC from WT mice with diet-induced NASH expressed 12 fold higher levels 
of OPN mRNA than chow diet-fed controls.  CM from WT mice-derived LMNC  that were treated 
with GC to activate resident NKT cells stimulated cultured HSC to express collagen mRNA, 
whereas similarly treated LMNC from two different strains of NKT cell deficient mice did not. These 
results indicate that activated liver NKT cells promote the production of factors that drive fibrogenic 
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responses in HSC, and suggest that one of these pro-fibrogenic factors might be OPN.  Indeed, 
ELISA demonstrated that CM from GC-activated WT LMNC contained four times more OPN than 
CM from similarly-treated LMNC populations from NKT cell deficient mice. Moreover, neutralizing 
OPN activity with OPN aptamers significantly abrogated the HSC fibrogenic responses to WT 
LMNC-derived factors, reducing HSC expression of collagen mRNA to basal levels. The 
aggregate findings, therefore, complement and extend earlier evidence that liver NKT cells are 
capable of producing OPN by showing that important fibrogenic actions of NKT cells are directly 
mediated by OPN (17, 24). 
 
Our studies in human subjects support the pathophysiological relevance of excessive OPN 
production during NASH fibrogenesis. Notably, we provide evidence that the upregulation of liver 
OPN production in advanced NASH is mirrored by increased plasma OPN levels. Recent reports 
suggest that high plasma OPN levels may also be predictive of cirrhosis in patients with chronic 
hepatitis B and C (150, 151). In addition, elevated plasma OPN levels are associated with cancer 
development, recurrence, and bad prognosis (175, 176). Given these observations, it is 
conceivable that plasma OPN levels might be used to identify NASH patients who are at high risk 
of bad outcomes. Further studies, in a larger cohort of individuals with NAFLD, will be necessary 
to confirm the clinical utility of this novel biomarker.  
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Chapter 7 
 
 
1. OPN is upregulated by Hh pathway activation in chronic liver injury and promotes 
liver fibrosis 
 
OPN gene and protein expressions are upregulated in animal models of CLD and in liver tissues 
obtained from patients with advanced liver disease (cirrhosis). Importantly, excess OPN has a 
direct pathogenic role as it can directly promote HSC activation. OPN neutralization conversely, 
prevents this.  
 
By manipulating Hh pathway activity with pharmacologic agents in cell cultures, we confirmed that 
Hh signaling regulates OPN gene and protein expression. These findings were supported by 
observations in primary HSC from mice with an overly active Hh pathway. OPN neutralization 
attenuated the fibrogenic responses despite persistent Hh pathway activation, therefore confirming 
that OPN is a downstream effector of the Hh pathway.  
 
2. OPN is proximal effector of leptin mediated liver fibrosis 
 
Both OPN and leptin promote liver fibrosis and are regulated by the Hh pathway. In HSC and total 
liver, leptin induces OPN expression. Through genetic and pharmacologic approaches, we further 
show that leptin fibrogenic effects are OPN dependent and that regulation of OPN expression 
occurs via leptin induced PI3K/Akt signaling.  
 
3. OPN enhances the LPC response in CLD 
OPN increases LPC proliferation, promotes EMT, and enhances the wound healing response in 
different models of study (two mouse LPC lines and in three mouse models of liver fibrosis). 
Conversely, OPN neutralization abrogates the LPC response in vitro and in vivo, and reduces liver 
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fibrosis. Specifically, OPN effects are achieved by modulating levels of Ski and SnoN, two 
corepressors of the TGF-signaling pathway. 
 
4. NKT cell derived OPN promotes NASH fibrosis 
 
NKT cells are the key immune cells which drive liver fibrosis, as confirmed in different models 
(GC-activated primary MNC / NKT cells and two genetic mouse models of NKT deficiency). NKT 
cells secrete OPN which promotes HSC activation. Mice deficient in NKT numbers exhibit a global 
reduction in liver OPN and develop less fibrosis.  
 
Final Conclusion: 
 
This body of research shows that OPN is upregulated during CLD and promotes fibrogenesis by 
activating HSC and LPCs. OPN is secreted by multiple cell types including HSCs, LPCs, and 
recruited NKT cells, which amplify the fibrogenic responses. In vivo, OPN neutralization abrogates 
the LPC response and reduces liver fibrosis, thus demonstrating that targeting OPN is a potentially 
attractive anti-fibrotic strategy. 
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